

PHENOL COMPOUND AND PROCESS FOR PREPARING THE SAME

BACKGROUND OF THE INVENTION

5 This invention relates to a novel phenol compound and a process for preparing the same.

An increase of ischemic heart failure diseases caused by accumulation of cholesterol in an arterial wall such as
10 atherosclerosis, cardiac infarction becomes social problems in the world.

As of today, medicines for decreasing the amount of blood cholesterol has been developed, but none of medicine which
15 can reduce an absorption of cholesterol at small intestine or an accumulation of cholesterol in an arterial wall, or which can reduce directly atherosclerosis itself has been found.

20 As an initial pathological change in atherosclerosis, accumulation of foam cells derived from monocytes/macrophages at the subendothelial space of an arterial wall is observed. Accumulation of lipid droplets into the foam cells is occurred by that 1) a low-density lipoprotein (LDL)
25 in blood is chemically modified at the subendothelial space of an arterial wall and incorporated by monocytes/macrophages through scavenger receptors, 2) the incorporated modified LDL is hydrolyzed in lysosomes, and the formed free cholesterol is transferred to cytoplasm, 3) it is re-
30 esterified by acyl co-enzyme A cholesterol acyl transferase (ACAT) at the cytoplasm and accumulated as lipid droplets whereby foam cell formation, which leads to pathological change of atherosclerosis. Thus, by preventing the action of the ACAT, it is possible to prevent either the incorporation of cholesterol into a body or formation of
35 cholesteryl esters.

As a compound having an activity of inhibiting ACAT, there may be described in, for example, Japanese Patent First Publications (Kokai) No. 188568/1990 and No. 92950/1990. However, the compounds described in the above references
5 have ACAT inhibiting action but no effect on oxidative modification of LDL which plays an important role in the foam cell formation of macrophages in the development of atherosclerosis has been shown.

10 By the way, the foam cells which play an important role in the formation of atherosclerosis are derived from macrophages as the result of taking oxidatively modified LDL in the macrophages. Thus, the fact that the LDL which is oxidatively modified causes foam cell formation of macro-
15 phages and plays an important role in the development of the atherosclerosis has been reported by Diane W. Morel, et al. (see ARTERIOSCLEROSIS, vol. 4, pp. 357-364, 1984). Also, it has been clarified by the report of TORU KITA, et al. (Proc. Natl. Acad. Sci. USA, vol. 84, pp. 5928-5931,
20 1987) that the prevention of oxidative modification of LDL leads the reduction of atherosclerosis. Accordingly, in addition to preventing ACAT as mentioned above, it is extremely important to inhibit oxidative modification of the LDL for preventing formation, development, and reduc-
25 tion of atherosclerosis.

On the other hand, it has not yet been completely clarified how the peroxidation reaction of lipids to causes damage of cell membranes and finally leads to cell death, but it has
30 been understood as a common recognition that production and accumulation of active oxygen plays an important role in the cell damages. Further, it is well-known that an active oxygen causes not only peroxidation of lipids but also modification of an enzyme or a protein and damage of a
35 nucleic acid, and these results induce various organ failures. For example, in heart, at an initial stage of


myocardial infarction caused by coronary occlusion, a patient falls into critical condition such as cardiogenic shock or lethal arrhythmia so that a reperfusion treatment (deformation of thrombus, percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG), etc.) for resuming blood flow is carried out as an initial treatment. However, in recent years, so-called ischemia/reperfusion injury in which cardiac muscle tissue is damaged by resuming blood flow has been noticed. It has been reported as problems that an active oxygen participates in the phenomenon as one of factors, and that oxygen radicals generated at the reperfusion cause reperfusion arrhythmia whereby cardiac muscle dysfunction is brought about by cell injury accompanied by decrease of ATP production or cell membrane destruction accompanied by increase of enzyme activities.

SUMMARY OF THE INVENTION


The present invention is to provide a novel phenol derivative having an antioxidative action which is effective for controlling atherosclerosis, cardiac infarction, cell damage and arrhythmia at ischemia/reperfusion by scavenging an active oxygen. Also, the present invention provides a process for preparing such a novel phenol derivative.

In order to solve the above problems, the present inventors by an exhaustive research have found that a novel phenol derivative controls development of atherosclerosis by inhibiting formation of foam cells of macrophage by an excellent anti-oxidative action and ACAT inhibiting action and controls myocardial infarction, cell damage and arrhythmia at ischemia/reperfusion by an excellent active oxygen scavenging action and anti-oxidative action, whereby accomplished the present invention.

That is, the present invention provides a phenol derivative represented by the formula (1):




5 wherein R⁰ represents hydrogen atom, an alkyl group
 which may be substituted or an alkyloxy group which
 may be substituted; R¹ represents an alkyl group which
 may be substituted; R² represents an alkyl group which
 may be substituted or an alkyloxy group which may be
 10 substituted; OR³ represents a hydroxyl group which may
 be protected; R⁴ represents hydrogen atom, a lower
 alkyl group or acyl group each of which may be substi-
 tuted; W represents O, S or NR⁷; wherein R⁷ represents
 15 hydrogen atom, an alkyl group, an aryl group, hydroxyl
 group or an alkyloxy group, a group of the formula
 (2):



 represents an amino group which may be mono- or di-
 substituted or a heterocyclic group containing
 20 nitrogen atom,
 or a pharmaceutically acceptable salt thereof.

Also, the present invention provides the process for
 preparing the above compound (1) or a pharmaceutically
 25 acceptable salt thereof according to the present invention
 comprising the steps of
 A) allowing a compound represented by the formula (c) or a
 reactive derivative thereof:




wherein R^0 , R^1 , R^2 and R^4 have the same meanings as defined above, OR^{31} represents a hydroxyl group which may be protected; and W^1 represents O or S.

5 to react with an amine compound represented by the formula (b):




wherein NR^5R^6 represents an amino group which may be mono- or di-substituted or a heterocyclic group containing nitrogen atom,

10 or a salt thereof to form a compound represented by the formula (1-a):



15 wherein the respective symbols have the same meanings as defined above; or

B) allowing an aniline compound represented by the formula (d):




20 wherein the respective symbols have the same meanings as defined above,

or a salt thereof to react with a reactive derivative of a carbamic acid compound represented by the formula (e):



25 wherein the respective symbols have the same meanings as defined above,

to form a compound represented by the formula (1-b):




wherein the respective symbols have the same meanings
as defined above; or

C) allowing the aniline compound represented by the above
formula (d) to react with an isocyanate (or thioisocyanate)
compound represented by the formula (f):



wherein R^{51} represents hydrogen atom, an alkyl group
which may be substituted, an alkenyl group which may
be substituted, an aryl group which may be substi-
tuted, an amino group which may be substituted or a
heterocyclic group, and the other symbol has the same
meaning as defined above,

to form a compound represented by the formula (1-c):




wherein the respective symbols have the same meanings
as defined above; and, if necessary,

D) when the group W^1 of the product represented by the
formula (1-a) or (1-c) is sulfur atom, if desired, allowing
the product (1-a) or (1-c) to react with an amine compound
represented by the formula (g):



wherein R^7 represents hydrogen atom, an alkyl group,
an aryl group, hydroxyl group or an alkyloxy group,
to form a compound of the formula (1-d):



wherein the respective symbols have the same meanings as defined above, and

5 E) when the group OR^{31} of the product is a protected hydroxyl group, removing the protecting group of said hydroxyl group, if desired, or when the group OR^{31} of the product is hydroxyl group, if desired, after protecting the hydroxyl group, and converting the product to a pharmaceutically acceptable salt, if desired.

10

DESCRIPTION OF THE PREFERRED EMBODIMENTS

As the alkyl group, which may be substituted, represented by R^0 in the phenol derivative (1) of the present invention, there may be mentioned an alkyl group having 1 to 20 carbon atoms, and preferably a straight or branched lower alkyl group such as methyl group, ethyl group, isopropyl group or hexyl group, octyl group and hexadecyl group. As the alkyloxy group, which may be substituted, represented by R^0 , there may be mentioned an alkyloxy group having 1 to 20 carbon atoms, and preferably a lower alkyloxy group such as methoxy group, octyloxy group and tetradecyloxy group, particularly methoxy group. As the R^0 , hydrogen atom is particularly preferred.

25

As the alkyl group, which may be substituted, represented by R^1 , there may be mentioned an alkyl group having 1 to 20 carbon atoms, preferably a straight or branched lower alkyl group such as methyl group, ethyl group, isopropyl group or hexyl group, octyl group and hexadecyl group, particularly preferably methyl group.

30

As the alkyl group, which may be substituted, represented by R^2 , there may be mentioned an alkyl group having 1 to 20 carbon atoms, preferably a straight or branched lower alkyl group such as methyl group, ethyl group or tert-butyl group, octyl group, decyl group and tetradecyl group, particularly preferably a branched lower alkyl group such as tert-butyl group. Also, as the alkyloxy group, which may be substituted, represented by R^2 , there may be mentioned an alkyloxy group having 1 to 20 carbon atoms, and preferably a lower alkyloxy group such as methoxy group, octyloxy group and tetradecyloxy group, particularly preferably methoxy group.

As the protecting group for the hydroxyl group, which may be protected, represented by OR^3 , a conventional protecting group which can be a protecting group for hydroxyl group can be used, and there may be mentioned, for example, an acyl group, a lower alkyloxy-lower alkyl group, a lower alkyloxycarbonyl group, a lower alkylcarbonyloxy-lower alkyl group and an aralkyl group.

Also, when the hydroxyl group which may be protected is protected by an acyl group, as the said acyl group, there may be mentioned an aliphatic acyl group or an aromatic acyl group, and particularly preferably a lower alkyl-carbonyl group or a lower cycloalkylcarbonyl group as the aliphatic acyl group.

Herein, the said acyl group may have a substituent, and there may be mentioned a group in which hydroxyl group is removed from a carboxyl group of an α -amino acid such as alanine, valine, glycine, aspartic acid, glutamic acid and lysine. The amino group of the group in which hydroxyl group is removed from a carboxyl group of an α -amino acid may be protected, and as the protecting group for the amino group, there may be mentioned, for example, an acyl group

including a lower alkylcarbonyl group such as acetyl group and propionyl group, a lower alkyloxycarbonyl group, and a phenyl lower alkyloxycarbonyl group such as benzyloxycarbonyl group.

5


As a preferred example of the hydroxyl group, which may be protected, represented by OR^3 , there may be mentioned hydroxyl group, a lower alkylcarbonyloxy-lower alkyloxy group (e.g., tert-butylcarbonyloxymethoxy group), an
10 acyloxy group (e.g., a lower alkylcarbonyloxy group such as acetyloxy group and ethoxycarbonyloxy group, benzoyloxy group, glycyloxy group, alanyloxy group, valyloxy group, aspartyloxy group, glutamyloxy group and lysiloxy group), and particularly preferred is hydroxyl group.

15

Among the substituents represented by R^4 , as the acyl group, there may be mentioned a lower alkylcarbonyl group such as acetyl group, and a group in which hydroxyl group is removed from a carboxyl group of an α -amino acid such as
20 glycyl and alanyl, and as the alkyl group which may be substituted, there may be mentioned an alkyl group having 1 to 20 carbon atoms (e.g., a straight or branched lower alkyl group such as methyl group, ethyl group, isopropyl group or hexyl group, octyl group and hexadecyl group,
25 particularly methyl group), and a heterocyclic group-substituted lower alkyl group (e.g., pyridylmethyl group), and as the R^4 , hydrogen atom is preferred.

When W is represented by NR^7 , the alkyl group in R^7 may
30 include a lower alkyl group such as methyl group and ethyl group, the aryl group in R^7 may include phenyl group, the alkyloxy group in R^7 may include a lower alkyloxy group such as methoxy group and ethoxy group. As W, oxygen atom or sulfur atom is preferred and oxygen atom is particularly
35 preferred.

As R^5 and R^6 when the group represented by the formula (2):



- is an amino group which may be mono- or di-substituted, these may be the same or different and may be mentioned
- 5 hydrogen atom, an alkyl group which may be substituted, an alkenyl group which may be substituted, an aryl group which may be substituted, an amino group which may be substituted and a heterocyclic group.
- 10 Among them, as the alkyl group which may be substituted, there may be mentioned an alkyl group, a halogenated alkyl group, a carboxyalkyl group, an alkyloxycarbonylalkyl group, a hydroxyalkyl group, a dihydroxyalkyl group, a trihydroxyalkyl group, an N-alkylaminoalkyl group, an N,N-
- 15 dialkylaminoalkyl group, an N-(diphenylalkyl)aminoalkyl group, a carbamoylalkyl group, an N-alkylcarbamoylalkyl group, an N,N-dialkylcarbamoylalkyl group, an N-(dihydroxyalkyl)carbamoylalkyl group, a morpholinocarbonylalkyl group, a heterocyclic group-substituted alkyl group, a
- 20 cycloalkyl group, a cycloalkylalkyl group, an arylalkyl group and a diarylalkyl group. As the alkenyl group which may be substituted, there may be mentioned an alkenyl group which have one or more double bonds and have 2 to 20 carbon atoms, preferably 2 to 8 carbon atoms, and those may be
- 25 substituted by one or more alkyl groups.

As the amino group which may be substituted, there may be mentioned amino group, a monoalkylamino group, a dialkylamino group, an arylamino group, an arylsulfonylamino group


30 and an arylcarbamoylamino group.

As the heterocyclic group and the heterocyclic group portion, there may be mentioned a saturated or unsaturated 3 to 12-membered monocyclic or dicyclic heterocyclic group

35 containing a hetero atom(s) selected from sulfur atom,

oxygen atom and nitrogen atom, and particularly preferred are those having 5 to 10-membered ring such as pyridyl group, pyridinio group, piperadinyll group, pyrrolidinyl group, morpholinyl group, pyradinyll group, piperidyl group, 5 imidazolidinyl group, imidazolyl group, benzimidazolyl group, quinolyl group, tetrahydroquinolyl group and pyrazolinyll group. These heterocyclic groups may be, if necessary, mono-, di- or tri-substituted by 1 to 3 groups selected from hydroxyl group, a hydroxyalkyl group, an 10 alkyloxy group, an alkyloxycarbonyl group, an alkylcarbonyl group, an alkyl group, a cycloalkyl group, a cycloalkylalkyl group, a pyridylalkyl group, oxo group, carboxyl group, phenyl group, a phenylalkyl group, a diphenylalkyl group, phenylpiperadinyll group, a phenylalkyloxycarbonyl 15 group, an N-phenylcarbamoyl group and an N-phenylcarbamoylaminoalkyl group (the above-mentioned phenyl group or phenyl portion may be, if necessary, mono-, di- or tri-substituted by 1 to 3 substituents selected from a halogen atom, hydroxyl group, an alkyl group, an alkyloxy group, a 20 dialkylaminoalkyloxy group, a cyano group, a dialkylamino group and trifluoromethyl group).

When the group represented by the formula (2):



25 is a nitrogen-containing heterocyclic group, that is, R^5 and R^6 are each bonded at their terminals to form a nitrogen-containing heterocyclic group with the adjacent nitrogen atom, said nitrogen-containing heterocyclic group may include a saturated or unsaturated 3 to 12-membered 30 mono-cyclic or di-cyclic nitrogen-containing heterocyclic group which may further contain one or two hetero atoms selected from sulfur atom, oxygen atom and nitrogen atom in addition to the original nitrogen atom, and preferred are those having 5 to 10-membered ring. More specifically, 35 there may be preferably mentioned, for example, piperazinyl

group, piperidino group, piperidyl group, morpholino group, morpholinyl group, pyrrolidinyl group, thiomorpholinyl group, imidazolidinyl group, dihydroquinolyl group and tetrahydroquinolyl group. These nitrogen-containing
5 heterocyclic group may be, if desired, mono-, di- or tri-substituted by 1 to 3 groups selected from the group consisting of a halogen atom, an alkyl group, hydroxyl group, a hydroxyalkyl group, an alkyloxy group, oxo group, carboxyl group, an alkyloxycarbonyl group, a phenylalkyl-
10 aminoalkyl group, phenyl group, a halogenophenyl group, an aminophenyl group, a nitrophenyl group, an aminophenyl-alkenyl group, an aminoalkyl group, an aminophenylalkyl group, an N,N-diaminoalkylaminophenylalkyl group, an N-arylhureidoalkyl group, a morpholinylphenylalkyl group, a
15 pyridylalkyl group, a benzimidazolylalkyl group, a hydroxyphenyl group, a diaminophenyl group, an N-alkylaminophenyl group, an N,N-dialkylaminophenyl group, an amidinophenyl group, a piperadinophenyl group, a morpholinophenyl group, pyrrolidinyl group, piperidyl group, indolyl group, pyrimidinyl group, benzimidazolyl group and pyridyl group.
20


As the above-mentioned cycloalkyl group and the cycloalkyl portion, there may be mentioned a cycloalkyl group having 3 to 10 carbon atoms, and these may be, if desired, mono-,
25 di- or tri-substituted by a substituent(s) selected from a halogen atom, an alkyl group, hydroxyl group, an alkyloxy group, amino group and an acylamino group.

Also, as the above-mentioned aryl group and the aryl
30 portion, there may be mentioned phenyl group and a naphthyl group, and these may be, if desired, mono-, di- or tri-substituted by 1 to 3 substituents selected from an alkyl group, an alkyloxy group, an alkylenedioxy group, a dialkylaminoalkyloxy group, cyano group, a halogen atom,
35 hydroxyl group, amino group, a mono-alkylamino group, a di-


alkylamino group, an acylamino group, trifluoromethyl group, an alkylthio group and carboxyl group.

5 The alkyl portion of the above-mentioned respective substituents may be either a straight or a branched, and if desired, these may be substituted by a substituent such as phenyl group, a phenylalkyl group, an aminoalkyl group, a cycloalkyl group and imidazolyl group.

10 Among the desired compounds (1) of the present invention, preferred compounds are compounds wherein R^0 is hydrogen atom, R^1 is an alkyl group, R^2 is an alkyl group, OR^3 is hydroxyl group, R^4 is hydrogen atom, W is oxygen atom, and the group represented by the formula (2):



is a mono- or di-substituted amino group, and particularly preferred are compounds wherein the group represented by the formula (2):



20 is a pyridyl-lower alkylamino group, an N,N-di(pyridyl-lower alkyl)amino group, an N-cycloalkyl-N-(phenyl-lower alkyl)amino group, an N-cycloalkyl-N-[(di-lower alkyl-amino)phenyl]amino group, an (aminophenyl)-piperadinyll group, an N-cycloalkylalkyl-N-(phenylalkyl)amino group, an
25 N-cycloalkylalkyl-N-phenylamino group, an N-cycloalkylalkyl-N-[(di-lower alkylamino)phenyl]amino group, an N-[(aminocycloalkyl)alkyl]-N-phenylamino group or an N-pyridyl-N-(pyridyl-lower alkyl)amino group.

30 Among the desired compounds of the present invention, particularly preferred are 2-[3-(3-pyridylmethyl)ureido]-4-methoxy-6-tert-butylphenol, 2-(3-cyclohexyl-3-phenylmethylureido)-4-methoxy-6-tert-butylphenol, 2-[3-cycloheptyl-3-(4-dimethylaminophenyl)ureido]-4-methoxy-6-tert-butyl-

phenol, 2-[3,3-di(pyridylmethyl)ureido]-4-methoxy-6-tert-butylphenol, 2-[4-(4-aminophenyl)piperazin-1-yl]amido-4-methoxy-6-tert-butylphenol, 2-[3-(2-cyclohexylethyl)-3-(4-dimethylaminophenyl)ureido]-4-methoxy-6-tert-butylphenol
5 and 2-[3-(4-pyridylmethyl)-3-(3-pyridyl)ureido]-4-methoxy-6-tert-butylphenol.

In the phenol derivative (1) of the present invention, optical isomers based on an asymmetric carbon can be
10 present, and the present invention includes both of the optical isomers and mixtures thereof.

The desired compound (1) of the present invention can be used for medical use in either a free form or in the form
15 of a pharmaceutically acceptable salt. As such a pharmaceutically acceptable salt, there may be mentioned, for example, an inorganic salt such as a hydrochloride, sulfate, hydrobromide and phosphate, and an organic salt such as an acetate, fumarate, succinate, maleate, methanesulfonate and p-toluenesulfonate. Also, when the compound has a
20 substituent such as a carboxyl group, it can be used in the form of a salt with a base (e.g., an alkali metal salt such as a sodium salt and a potassium salt, or an alkaline earth metal salt such as a calcium salt).

25 The desired compound (1) and the pharmaceutically acceptable salt thereof according to the present invention includes all of an intramolecular salt, adduct, complex, solvate and hydrate.

30 The desired compound (1) or a salt thereof of the present invention can be administered orally or parenterally, and according to the conventional manner, these can be used as a suitable pharmaceutical preparation such as a tablet,
35 granule, capsule, powder, injection and inhalant.

An administration dose of the desired compound (1) or the pharmaceutically acceptable salt thereof according to the present invention may vary depending on the method of administration, age, body weight or conditions of a patient, but the administration dose per day is generally about 5 to 50 mg/kg in the case of an oral administration and about 0.1 to 10 mg/kg in the case of a parenteral administration.

10 The compound (1) or a pharmaceutically acceptable salt of the present invention can be prepared, for example, by the steps A) to E) as mentioned above.

In the above steps, as the salt of the amine compound (b) or the aniline compound (d), there may be used, for example, a salt with an inorganic acid such as hydrochloride and sulfate, and a salt with an inorganic base such as an alkali metal salt and an alkaline earth metal salt.

20 [Method A]:

The condensation reaction of a compound (c) or a reactive derivative thereof and the amine compound (b) or a salt thereof can be carried out by a conventional method used for an amide-bond formation reaction in the presence or absence of a condensing agent such as 1,3-dicyclohexylcarbodiimide (DCC) and in the presence or absence of a base in a solvent or without a solvent.

30 As the base, there may be mentioned, for example, triethylamine, pyridine, dimethylaminopyridine, 1,8-diazabicyclo[5.4.0]-7-undecene and diisopropylethylamine, and as the solvent, there may be mentioned, for example, dichloromethane, chloroform, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, ethylene glycol, dimethylformamide, dimethylsulfoxide, toluene and benzene.

Examples of the salt of the amine compound (b) include a salt with an inorganic acid such as hydrochloride and sulfate, and a salt with an inorganic base such as an alkali metal salt and an alkaline earth metal salt.

5

The above reaction can be carried out under cooling to under heating, and, for example, it can be suitably carried out at -30 to 100 °C, particularly preferably at 0 to 50 °C.

10


As the reactive derivative of the compound (c), there may be used a compound which is conventionally used in an amide-bond formation reaction such as a corresponding acid halide, mixed acid anhydride and active ester.

15

The above reaction can be carried out by using the amine compound (b) or a salt thereof in an amount of 0.2 to 3 mole, preferably 0.5 to 1.5 mole per mole of the compound (c) or a reactive derivative thereof.

20

When a phenyl carbamate (phenyl carbamic acid ester) derivative represented by the formula (c-1):



25

wherein the symbols have the same meanings as defined above,

is used as the reactive derivative of the compound (c), the reaction of the derivative (c-1) and the amine compound (b) or a salt thereof can be carried out in a suitable solvent. As the solvent, there may be suitably used, for example, benzene, toluene, xylene, dichloromethane, tetrahydrofuran and chloroform.

30

The above reaction suitably proceeds at 50 to 150 °C, particularly at 50 to 100 °C.

- 5 The reaction can be carried out by using the amine compound (b) or a salt thereof in an amount of 0.2 to 2.0 mole per mole of the phenyl carbamate derivative (c-1).

[Method B]:

- 10 The reaction of the aniline compound (d) or a salt thereof and a reactive derivative of the carbamic acid compound (e) (e.g., an active ester such as phenyl ester) can be carried out in a suitable solvent such as benzene, cyclohexane, toluene, xylene, dichloromethane, chloroform, carbon
15 tetrachloride, diethyl ether and tetrahydrofuran.

- Examples of the salt of the aniline compound (d) include a salt with an inorganic acid such as hydrochloride and sulfate, and a salt with an organic acid such as methane-
20 sulfonate and p-toluenesulfonate.

The above reaction suitably proceeds at 50 to 150 °C, particularly at 50 to 100 °C.

- 25 The reaction can be carried out by using the reactive derivative of the carbamic acid compound (e) in an amount of 0.2 to 2.0 mole per mole of the aniline compound (d) or a salt thereof.

- 30 [Method C]:

- The reaction of the aniline compound (d) or a salt thereof and the isocyanate (or thioisocyanate) compound (f) can be carried out in a suitable solvent such as dichloromethane, chloroform, 1,2-dichloroethane, diethyl ether, tetrahydro-
35 furan, dioxane, ethylene glycol, dimethylformamide,

dimethylacetamide, dimethylsulfoxide, toluene, benzene, hexamethylphosphoramide, sulforan and 1,3-dimethyl-2-imidazolidinone or without a solvent.

- 5 As the aniline compound (d) or a salt thereof, there may be mentioned those as mentioned in the above Method B.

The above reaction suitably proceeds at -30 to 100 °C, particularly at 0 to 50 °C.

10

The reaction can be carried out by using the isocyanate (or thioisocyanate) compound (f) in an amount of 0.2 to 3.0 mole, preferably 0.5 to 1.5 mole per mole of the aniline compound (d) or a salt thereof.

15

[Method D]:

20 The reaction of the compound (1-a) or (1-c) and the amine compound (g) can be carried out in the presence of a solvent (e.g., methanol, ethanol, dioxane, ethylene glycol, dimethylacetamide, benzene, toluene, chloroform, dichloromethane, dimethylsulfoxide and dimethylformamide) or in the absence of a solvent.

- 25 The above reaction can be suitably carried out at 0 to 200 °C, particularly at 25 to 100 °C.

30 The reaction can be carried out by using the amine compound (g) in an amount of 0.2 to 10 mole, preferably 0.5 to 3 mole per mole of the compound (1-a) or (1-c).

35 In the above mentioned [Method A], [Method B], [Method C] and [Method D], when OR³¹ is a protected hydroxyl group, if desired, the protecting group for the said hydroxyl group may be removed according to the conventionally known method. Removal of the said protecting group can be

carried out depending on the kind of the protecting group according to the conventionally known method such as hydrolysis, acid treatment or reduction.

- 5 When OR^3 of the desired compound (1) is hydroxyl group, if desired, the hydroxyl group can be protected by, for example, acylation according to the conventionally known method. The acylation reaction can be carried out according to the conventional manner by using, for example, a
10 free acid of an amino acid, a cycloalkanoic acid or an alkanolic acid which may have a substituent, or a reactive derivative thereof.

- As the reactive derivative thereof, there may be mentioned
15 an acid halide, an acid anhydride, an activated amide or an activated ester.

- The reaction can be carried out according to the conventional manner, and when, for example, an acid halide
20 compound is used as an acylating agent, it can be suitably carried out in the presence of a base (e.g., triethylamine, pyridine, 4-N,N-dimethylaminopyridine, 1,8-diazabicyclo-[5.4.0]-7-undecene and sodium hydride) in a suitable solvent (e.g., dichloromethane, tetrahydrofuran and
25 dimethylformamide) or without any solvent.

- When a free acid is used as an acylating agent, the reaction is preferably carried out in the presence of a condensing agent which is conventionally used in an ester-
30 bond formation reaction.

- The protection of the hydroxyl group with a lower alkyloxy-carbonyl group can be carried out in the same manner as in the above acylation reaction by using a halogenated-lower
35 alkyl carbonate. Also, the conventionally used protecting group can be introduced into hydroxyl group according to

the conventional manner.

The desired compound (1) of the present invention can be also prepared by mutually converting the obtained compound
5 as mentioned above to another compound. Such a mutual conversion reaction of the desired compounds (1) can be optionally selected depending on the kind of a substituent in the compound (1), and, for example, the reaction can be carried out as mentioned in the following methods (a) to
10 (c).


Method (a):

The compound (1) having a carboxyl group in the substituent
15 R^5 or R^6 can be prepared by subjecting a corresponding derivative (1) having a protected carboxyl group (e.g., a carboxyl group protected by a protecting group such as an alkyl group and an arylalkyl group) to the conventional deprotection reaction of the protecting group such as a
20 hydrolysis or hydrogenolysis.

The hydrolysis can be carried out, for example, in the presence of a base (e.g., an inorganic base such as sodium hydroxide). The hydrogenolysis can be carried out, for
25 example in the presence of a catalyst such as palladium on an activated carbon under an atmosphere of hydrogen. The both deprotection reaction proceeds at 0 °C to 60 °C.

Method (b):

30 The desired compound (1) having an amide group in the substituent R^5 or R^6 can be prepared by subjecting a corresponding compound (1) in which the substituent $-NR^5R^6$ of the compound (1) is a group containing a free carboxyl group
35 and an amine compound represented by the formula (h):



wherein $-\text{NR}^8\text{R}^9$ represents an amino group which may be mono- or di-substituted or a heterocyclic group containing nitrogen atom,

5 to condensation reaction.

The condensation reaction can be carried out in the... presence of a dehydrating agent, and as the dehydrating agent, there may be used, for example, 1,3-dicyclohexyl-
10 carbodiimide (DCC). The reaction suitably proceeds at 0 to 50 °C.

Method (c):

15 The desired compound (1) wherein the group $-\text{NR}^5\text{R}^6$ is a mono-alkyl substituted or di-alkyl substituted amino group can be prepared by allowing the compound (1) wherein the said group $-\text{NR}^5\text{R}^6$ is an unsubstituted or a mono-substituted amino group to react with an alkylating agent represented
20 by the formula (i):



wherein R^{10} represents an alkyl group which may be substituted and X represents a leaving group.

25 Alkylation can be carried out in the presence of an acid acceptor by reacting with an alkyl halide (e.g., alkyl chloride, and alkyl bromide and alkyl iodide), alkyl alkanesulfonate (e.g., alkyl methanesulfonate) or an alkyl arylsulfonate (e.g., alkyl toluenesulfonate).


30

As the acid acceptor, there may be suitably used an alkali metal hydroxide, alkali metal hydrogen carbonate, alkali metal carbonate and an organic base (e.g., triethylamine,

diisopropylethylamine and pyridine). This reaction suitably proceeds at 0 to 50 °C.

5 The solvent to be used in the reactions described in the above mentioned Methods (a) to (c) is not particularly limited so long as it is inert to the reaction, and may be suitably used, for example, dioxane, ethylene glycol, dimethylacetamide, dimethylformamide, hexamethylphosphor-
10 amide, benzene, tetrahydrofuran, toluene, ethyl acetate, a lower alcohol, dichloromethane, 1,2-dichloroethane, chloroform, carbon tetrachloride, 1,3-dimethyl-2-imidazolidinone, diethyl ether, dimethoxyethane, dimethylsulfoxide, carbon disulfide, acetone, water or a mixed solvent of the above.

15 The reactive derivative of the intermediate compound (c) according to the present invention such as a corresponding acid halide can be prepared by, for example, allowing an aniline compound represented by the formula (d):



20 wherein the respective symbols have the same meanings as defined above,
or a salt thereof to react with phosgene, triphosgene or thiophosgene.

25 The reaction of the aniline compound (d) or a salt thereof and phosgene, triphosgene or thiophosgene can be suitably carried out in the presence of a base in a suitable solvent or without solvent.

30 As the base, there may be suitably used triethylamine, pyridine, 4-N,N-dimethylaminopyridine, 1,8-diazabicyclo-[5.4.0]-7-undecene and diisopropylethylamine, and as the solvent, there may be suitably used dichloromethane,


chloroform, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, dimethylformamide, dimethylsulfoxide, toluene and benzene.

- 5 The reaction suitably proceeds at -30 to 100 °C, particularly at 0 to 50 °C.

The reaction can be carried out by using phosgene, triphosgene or thiophosgene in an amount of 0.2 mole to 5 mole, preferably 0.5 mole to 2 mole per mole of the aniline
10 compound (d) or a salt thereof.

The starting compounds (b), (d) and (f) of the present invention can be prepared, for example, by the methods
15 mentioned below.

Among these compounds, the aniline compound (d) wherein R⁴ is hydrogen atom can be prepared by subjecting the compound represented by the formula (j):



20

wherein the symbols have the same meanings as defined above,

to the introduction of an azo group or an azido group therein and then subjecting to reduction.


25

The aniline compound (d) wherein R⁴ is an alkyl group or an acyl group can be prepared, if desired, by introducing one protecting group for the amino group of the aniline compound (d) wherein R⁴ is hydrogen atom, allowing the resulting compound to react with a compound represented by the
30 formula (n):



wherein X represents a halogen atom and R⁴¹ represents an alkyl group or an acyl group, and, if desired, removing the protecting group.

- 5 The amine compound (b) wherein the group represented by the formula (2):



- is a mono- or di-substituted amino group can be prepared, for example, by allowing the compound represented by the
10 formula (p):



wherein Z¹ represents a protecting group for amino group and other symbol has the same meaning as defined above,

- 15 to react with the compound represented by the formula (q):




- wherein R⁶¹ represents a substituent (e.g., an alkyl group, an alkenyl group, an aryl group, an amino group or heterocyclic group) for amino group and Y represents a halogen atom,
20 and then removing the protecting group.

- The compound (f) can be prepared, for example, by allowing the amine compound (b) wherein R⁶ is hydrogen atom to react
25 with phosgene, triphosgene or thiophosgene in the presence of a conventionally used base (e.g., triethylamine and pyridine).

- The reactive derivative of the carbamic acid compound (e)
30 or the phenyl carbamate derivative (c-1) can be prepared, for example, by allowing the amine compound (b) or the aniline compound (d) to react with phenyl chloroformate.

The compound (j) wherein R^{31} is hydrogen atom can be prepared, for example, by treating the benzaldehyde derivative represented by the formula (k):




5 wherein the symbols have the same meanings as defined above,

with a peroxide such as hydrogen peroxide (Baeyer-Villiger Reaction), and then subjecting the resulting compound to hydrolysis.

10

Further, the compound (k) can be prepared by a conventional manner, for example, by halogenating the compound represented by the formula (m):



15 wherein the symbols have the same meanings as defined above,

with bromine, etc., followed by lithionating the halogenated product and then subjecting the resulting compound to formylation with N,N-dimethylformamide and the like.

20

When the compound represented by the formula (d), (c-1) or (j) has hydroxyl group, the hydroxyl group can be protected by a protecting group such as methoxymethyl group, if desired, in each of the steps for preparing the compound (1). Also, the said protecting group can be easily removed by the conventional manner such as a treatment with an acid (e.g., hydrochloric acid).

25

As the protecting group for the amino group, there may be mentioned a conventionally used protecting group which is

30

available for protection of the amino group such as benzyl-oxycarbonyl group and tert-butoxycarbonyl group.


5 The desired compound (1) of the present invention can be converted into a pharmaceutically acceptable salt by the conventional manner, if desired.

10 In the present specification, as the alkyl group and alkyl portion, there may be mentioned an alkyl group and an alkyl portion having 1 to 20 carbon atoms, preferably 1 to 10 carbon atoms, particularly 1 to 6 carbon atoms. As the lower alkyl group and lower alkyl portion, there may be mentioned those having 1 to 6 carbon atoms, particularly 1 to 4 carbon atoms. As the alkenyl group, there may be
15 mentioned that having 2 to 20 carbon atoms, particularly 2 to 7 carbon atoms. As the lower alkenyl group and lower alkenyl portion, there may be mentioned those having 2 to 8 carbon atoms, particularly 2 to 5 carbon atoms. As the cycloalkyl group, there may be mentioned that having 3 to
20 10 carbon atoms, particularly 5 to 8 carbon atoms. As the halogen atom, there may be mentioned chlorine atom, bromine atom, fluorine atom or iodine atom. As the aryl group, there may be mentioned, for example, a phenyl group and a naphthyl group. As the alkylenedioxy group, there may be
25 mentioned an alkylenedioxy group having 1 to 6 carbon atoms.

EXAMPLES

30 In the following, specific synthetic methods of the compounds according to the present invention are described as examples.

Example 1



(1) A tetrahydrofuran (THF) (20 ml) containing 2.4 g of (2-amino-4-methoxy-6-tert-butylphenoxy)methoxymethane and 1.09 ml of phenyl isocyanate was stirred at room temperature for 3 hours, and then the solvent was removed under reduced pressure. The obtained residue was crystallized from hexane, and recrystallized from an ethyl acetate-hexane mixed solution to give 2.3 g of [2-(3-phenylureido)-4-methoxy-6-tert-butylphenoxy]methoxymethane (yield: 64 %, melting point: 121-123 °C, IR: 3300, 1650 cm⁻¹).

NMR (δ ppm, CDCl₃): 1.34 (9H, s), 3.55 (3H, s), 3.78 (3H, s), 4.95 (2H, s), 6.60 (1H, d, J=3Hz), 6.81 (1H, s), 7.03-7.41 (5H, m), 7.63 (1H, d, J=3Hz), 8.05 (1H, s)

15


(2) Conc. hydrochloric acid (1.5 ml) was added to 30 ml of a methanol solution containing 2.2 g of [2-(3-phenylureido)-4-methoxy-6-tert-butylphenoxy]methoxymethane and the mixture was stirred at room temperature for 1.5 hours. The solvent was removed under reduced pressure and the residue was extracted with ethyl acetate. The extract was washed and dried, and the solvent was removed under reduced pressure. Hexane was added to the residue and the resulting crystals were collected by filtration and recrystallized from a mixed solution of ethyl acetate and hexane to give 1.6 g of 2-(3-phenylureido)-4-methoxy-6-tert-butylphenol (yield: 83 %, melting point: 147-149 °C, IR: 3400, 3350, 1670 cm⁻¹).

30 NMR (δ ppm, CDCl₃): 1.4 (9H, s), 3.67 (3H, s), 6.38 (1H, d, J=3Hz), 6.77 (1H, d, J=3Hz), 6.84 (1H, s), 7.05-7.33 (6H, m), 7.65 (1H, s)

Examples 2 to 13

The corresponding starting materials and phenyl isocyanate or phenyl isothiocyanate were treated in the same manner as described in Example 1 to give the compounds as shown in Tables 1 and 2.

Table 1

			
Example	R ² -	W	Melting point (°C)
2	CH ₃ -	O	173-176
3	CH ₃ (CH ₂) ₇ -	O	100-101
4	CH ₃ O-	O	172-174
5	CH ₃ (CH ₂) ₇ O-	O	66-68
6	CH ₃ (CH ₂) ₇ O-	S	114-116
7	CH ₃ (CH ₂) ₁₃ O-	O	64-67
8	CH ₃ (CH ₂) ₁₃ -	O	111-113
9	CH ₃ O-	S	131-134
10	CH ₃ CH ₂ -	O	150-152
11	(CH ₃) ₃ C-	S	134-136

(Note) each symbol represents the following:

Me: methyl group

Et: ethyl group

Pr: propyl group


Bu: butyl group

Ph: phenyl group


Boc: tert-butyloxycarbonyl group

hereinafter the symbols represent the same.

Table 2


			
Example	R¹-	W	Melting point (°C)
12	CH₃(CH₂)₇-	O	115-117
13	CH₃(CH₂)₁₅-	O	157-159

Example 14




(3-Amino-4,6-dimethoxyphenoxy)methoxymethane and phenyl isocyanate were treated in the same manner as described in Example 1 to give 3-(3-phenylureido)-4,6-dimethoxyphenol (melting point: 162-164 °C).

Example 15



(3-Amino-4,6-dimethoxyphenoxy)methoxymethane and phenyl isothiocyanate were treated in the same manner as described in Example 1 to give 3-(3-phenylthioureido)-4,6-dimethoxyphenol (melting point: 152-154 °C).

Example 16



(1) A dichloromethane (450 ml) solution containing 5.58 g of triphosgene was cooled to -78 °C, and after dropping 150 ml of a dichloromethane solution containing 11.25 g of (2-amino-4-methoxy-6-tert-butylphenoxy)methoxymethane and 20 ml of triethylamine. The temperature of the mixture was raised to 0 °C and the solvent was removed under reduced pressure. To the residue was added 200 ml of dichloromethane, and then 100 ml of a dichloromethane solution containing 5.08 g of 3-aminomethylpyridine and 10 ml of triethylamine was added dropwise to the mixture. The resulting mixture was further stirred for one hour. The reaction mixture was washed and dried, and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (solvent; chloroform : methanol = 15 : 1), and crystallized from isopropyl ether and further recrystallized from a mixed solution of isopropyl ether and ethyl acetate to give 13.97 g of {2-[3-(3-pyridylmethyl)ureido]-4-methoxy-6-tert-butylphenoxy}-methoxymethane (yield: 80 %, melting point: 108-109 °C).

20

(2) To 150 ml of a methanol solution containing 13.97 g of the above product was added 6.8 ml of conc. hydrochloric acid, and the mixture was stirred at room temperature for one hour. The reaction mixture was evaporated to dryness under reduced pressure and the crystalline residue was recrystallized from an ethanol solution to give 11.20 g of 2-[3-(3-pyridylmethyl)ureido]-4-methoxy-6-tert-butylphenol hydrochloride (yield: 82 %, melting point: 165-167 °C).

30 Examples 17 to 50

The corresponding starting materials were treated in the same manner as described in Example 16 to give the compounds as shown in Tables 3 to 8.

35

Table 3









			
Example	-R ⁶	W	Melting point (°C)
17		O	173-175
18	$-(CH_2)_2CH(OH)CH_2OH$	O	118-123
19		O	134-135
20		O	153-154
21		O	178-188
22	$-(CH_2)_2-\text{C}_6\text{H}_4-\text{O}-(CH_2)_3-\text{N}(\text{n-Bu})_2$	O	134-136
23	$-\text{CH}_2\text{CH}_2\text{Cl}$	O	126-128
24		O	86-87
25		O	153-154 (decomposed)
26		O	193-195 (decomposed)
27	$-\text{C}(\text{CH}_2\text{OH})_3$	O	169-170

Table 3 (contd.)








			
Example	-R ⁶	W	Melting point (°C)
28		O	137-139
29		O	147-148 (decomposed)
30		O	150-152
31		O	93-95
32		O	Powder IR: 3374, 1742, 1650, 1560 (cm ⁻¹)
33		O	Oily product IR: 3300, 1690, 1645, 1557 (cm ⁻¹)

Table 4



		
Example	-R ⁶	Melting point (°C)
34		135-137

Table 5

5








			
Example	-R ⁶	W	Melting point (°C)
35		O	200-202 (decomposed)
36		O	196-199
37		O	193-195
38		O	118-120
39		O	185-187
40		O	152-154

Table 5 (contd.)





			
Example	-R ⁶	W	Melting point (°C)
41		O	175-176
42		O	172-175
43		O	150-153

Table 6

5




			
Example	-R ⁶	W	Melting point (°C)
44		O	169-175 (decomposed)
45		O	191-193

Table 7





			
Example	-R ⁶	W	Melting point (°C)
46	$-(CH_2)_2-NH-\begin{matrix} \text{Ph} \\ \\ \text{Ph} \end{matrix}$	O	183-185

Table 8

5

		
Example	-R ⁶	Melting point (°C), etc.
47	$-NH-\text{C}_6\text{H}_5$	160-162
48	$-NHSO_2-\text{C}_6\text{H}_5$	198-199 (decomposed)
49	$-N(CH_3)_2$	150-153 monohydrochloride
50		175-176

Example 51




(1) A mixed solution comprising 25 ml of 1.847 M phosgene-
 10 dichloromethane and 130 ml of dichloromethane was cooled to

-78 °C, and to the solution was added dropwise a mixture comprising 5.5 g of (2-amino-4-methoxy-6-tert-butylphenoxy)methoxymethane, 9.6 ml of triethylamine and 50 ml of dichloromethane. After the reaction, the temperature of the mixture was raised to 0 °C and the solvent was removed under reduced pressure. The residue was dissolved in 70 ml of dimethylformamide (DMF) and the solution was added dropwise to a mixture of 3.45 g of hydrazine monohydrate, 4.8 ml of triethylamine and 70 ml of DMF, and the mixture was stirred at room temperature for 2 hours. Water was added to the reaction mixture and the reaction mixture was extracted with ethyl acetate. The extract was washed and dried, and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (solvent; ethyl acetate) and recrystallized from a mixed solution of isopropyl ether and ethyl acetate to give 3.5 g of [2-(3-aminoureido)-4-methoxy-6-tert-butylphenoxy]-methoxymethane (yield: 51 %, melting point: 132-134 °C).

(2) Conc. hydrochloric acid (3 ml) was added to 50 ml of a methanol solution containing 3.40 g of the above product, and the mixture was stirred at room temperature for 5 hours. The reaction mixture was evaporated to dryness under reduced pressure, an aqueous saturated sodium hydrogen carbonate solution was added to the residue to neutralize the mixture and the mixture was extracted with ethyl acetate. The extract was washed and dried, and the solvent was removed under reduced pressure. The crystalline residue was recrystallized from a mixed solution of isopropyl ether and ethyl acetate. The resulting crystals were dissolved in 20 ml of dichloromethane, and after adding 3.8 ml of 4N-hydrogen chloride-dioxane solution, and the mixture was evaporated to dryness under reduced pressure. Hexane was added to the residue to give 2.18 g of 2-(3-amino-ureido)-4-methoxy-6-tert-butylphenol hydrochloride as colorless powder (yield: 66 %).

Example 52



(1) Isobutyric acid (13.9 ml) was added dropwise to a mixture of 21.1 ml of 62.5 % sodium hydride, 93.8 ml of diisopropylamine and 150 ml of tetrahydrofuran (THF) at 30 °C or lower. After refluxing the mixture for 30 minutes, to the mixture was added 31.0 ml of a 1.6M n-butyl lithium-hexane solution at 10 °C or lower and the mixture was stirred for 15 minutes at the same temperature and for 2 hours at room temperature. At 10 °C or lower, 5.76 g of 1-bromodecane was added dropwise to the mixture. The mixture was stirred at the same temperature for one hour and then at room temperature overnight. After adding 300 ml of ice water, the reaction mixture was washed with diethyl ether, and the aqueous layer was adjusted to pH = 1 with conc. hydrochloric acid and extracted with isopropyl ether. After the extract was washed and dried, the solvent was removed under reduced pressure to give 2.36 g of 2,2-dimethylsuccinic acid (state: pale yellow oily product).


NMR (δ ppm, CDCl₃): 0.88 (3H, t, J=3Hz), 1.49 (6H, s), 1.10-1.65 (18H, m)

(2) A mixture of 5 g of 2,2-dimethylsuccinic acid, 4.72 ml of diphenylphosphoryl azide (DPPA), 3.36 ml of triethylamine and 80 ml of benzene was refluxed for one hour. After cooling, a mixed solution of 5.763 g of (2-amino-4-methoxy-6-tert-butylphenoxy)methoxymethane and 20 ml of benzene was added dropwise to the above mixture. The resulting mixture was stirred at room temperature for one hour and then under reflux for 10 hours. Water was added to the reaction mixture, and the reaction mixture was extracted with ethyl acetate. The extract was washed and dried, and the solvent

was removed under reduced pressure. The residue was purified by silica gel column chromatography (solvent; hexane : ethyl acetate = 4 : 1) and the product was recrystallized from hexane to give 2.89 g of {2-[3-(1,1-dimethylundecyl)-ureido]-4-methoxy-6-tert-butylphenoxy}methoxymethane (melting point: 83-85 °C).

(3) The product (2.75 g) thus obtained was dissolved in 50 ml of methanol, and after adding 1 ml of conc. hydrochloric acid, the mixture was stirred at room temperature for one hour. The solvent was removed under reduced pressure, water was added to the residue and the mixture was extracted with ethyl acetate. The extract was washed and dried, and the solvent was removed under reduced pressure. Hexane was added to the crystalline residue and the crystals were collected by filtration to give 0.778 g of 2-[3-(1,1-dimethylundecyl)ureido]-4-methoxy-6-tert-butylphenol (melting point: 99-102 °C).

Example 53



(1) A dichloromethane (100 ml) solution of 1.494 g of triphosgene was cooled to -78 °C, and to the solution was added dropwise a mixture of 3.012 g of (2-amino-4-methoxy-6-tert-butylphenoxy)methoxymethane, 5.3 ml of triethylamine and 60 ml of dichloromethane. The temperature of the mixture was raised to 0 °C, and the solvent was removed under reduced pressure. At room temperature, 100 ml of dichloromethane was added to the residue, and a mixture of 3.101 g of (2-cyclohexylethyl)-(4-dimethylaminophenyl)-amine, 2.6 ml of triethylamine and 50 ml of dichloromethane

was added dropwise. The mixture was further stirred at room temperature overnight. The reaction mixture was washed and dried, the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (solvent; chloroform : ethyl acetate = 15 : 1) and recrystallized from an isopropyl ether solution to give 3.3 g of {2-[3-(2-cyclohexylethyl)-3-(4-dimethylaminophenyl)ureido]-4-methoxy-6-tert-butylphenoxy}-methoxymethane (yield: 51 %, melting point: 108-110 °C).

(2) Conc. hydrochloric acid (3 ml) was added to a mixed solution of 3.183 g of the product thus obtained, 50 ml of methanol and 10 ml of dichloromethane, and the mixture was stirred at room temperature for 3 hours. The reaction mixture was evaporated to dryness under reduced pressure. An aqueous saturated sodium hydrogen carbonate solution was added to the residue and the mixture was extracted with ethyl acetate. The extract was washed with water and dried, and the solvent was removed under reduced pressure. The residue was dissolved in 20 ml of dichloromethane, and after adding 5 ml of 4N-hydrogen chloride-dioxane solution, the mixture was evaporated to dryness under reduced pressure. The residue was recrystallized from an ethyl acetate solution to give 1.63 g of 2-[3-(2-cyclohexylethyl)-3-(4-dimethylaminophenyl)ureido]-4-methoxy-6-tert-butylphenol hydrochloride (yield: 52 %, melting point: 112-116 °C).

Examples 54 to 132

The corresponding starting materials were treated in the same manner as described in Example 53 to give the compounds as shown in Tables 9 to 18.

Table 9























			
Example	-R ⁵	-R ⁶	Melting point (°C), etc.
54		-CH ₂ CH=C(CH ₃) ₂ CH=C(CH ₃) ₂ (Z)	130-132
55	-CH ₂ - 	-(CH ₂) ₆ CH ₃	75-77
56	-CH ₂ - 		140-141
57		 -(CH ₂) ₇ CH ₃	68-70
58	-CH ₂ - 		Powder IR: 3370, 1620, 1594 (cm ⁻¹)
59	-CH ₂ - 		153-154
60	-CH ₂ - 	-CH ₂ -  -N-C(=O)-N- 	142-144
61		-CH ₂ - 	124-126
62	-CH ₂ - 	-CH ₂ -  NBoc	158-160
63	-CH ₂ - 	-CH ₂ - 	122-125
64		-(CH ₂) ₂ - 	116-118

Table 9 (contd.)






















			
Example	-R ⁵	-R ⁶	Melting point (°C), etc.
65			141-142
66			129-130
67			144-148
68			121-123
69			Powder IR: 3336, 1730, 1629, 1518 (cm ⁻¹)
70			148-150
71			136-138
72			164-166
73			144-147
74			120-121

Table 9 (contd.)

















			
Example	-R ⁵	-R ⁶	Melting point (°C), etc.
75			118-119
76			140-142
77			137-139
78	-(CH ₂) ₃ NMe ₂		91-93
79			165-167
80		-(CH ₂) ₅ COOEt	132-134
81		-(CH ₂) ₃ COOEt	Oily product IR: 3340, 2955, 1732, 1639 (cm ⁻¹)
82		-(CH ₂) ₂ COOEt	68-70
83	-(CH ₂) ₃ COOEt		Powder IR: 1730, 1638 (cm ⁻¹)
84	-(CH ₂) ₃ COOEt		104-105
85	-(CH ₂) ₃ COOEt		115-116
86	-(CH ₂) ₃ COOEt		77-79

Table 9 (contd.)










			
Example	-R ⁵	-R ⁶	Melting point (°C), etc.
87	-(CH ₂) ₃ COOEt		99-101
88	-(CH ₂) ₃ COOEt		113-115
89	-(CH ₂) ₃ COOEt		119-120
90	-H	-(CH ₂) ₃ COOEt	69-71
91			169-171
92			124-127
93			Monohydrochloride 184-186

Table 10



			
Example	-R ⁵	-R ⁶	Melting point (°C)
94			130-132

Table 11

5













			
Example	-R ⁵	-R ⁶	Melting point (°C), etc.
95		$-(CH_2)_7CH_3$	156-159
96			183-185
97			140-142
98			Powder IR: 3240, 1610 (cm ⁻¹)
99			Powder IR: 3370, 1639 (cm ⁻¹)
100			Powder IR: 3240, 1616 (cm ⁻¹)

Table 11 (contd.)




















			
Example	-R ⁵	-R ⁶	Melting point (°C), etc.
101			173-175 (decomposed)
102			186-188
103			166-167
104			143-145
105			Powder IR: 3400, 1625 (cm ⁻¹)
106			146-148
107			Powder IR: 3380, 1630, 1594, 1510 (cm ⁻¹)
108			135-138
109		$-(CH_2)_6CH_3$	144-147
110			Powder IR: 3450, 1668, 1535, 1471 (cm ⁻¹)

Table 12




			
Example	-R ⁵	-R ⁶	Melting point (°C)
111			153-154

Table 13

5














			
Example	-R ⁵	-R ⁶	Melting point (°C), etc.
112			113-120
113			148-155
114			Powder IR: 3405, 1636 (cm ⁻¹)
115			Powder IR: 3424, 1637 (cm ⁻¹)
116			150-152
117			Powder IR: 3428, 1618 (cm ⁻¹)

Table 13 (contd.)












			
Example	-R ⁵	-R ⁶	Melting point (°C), etc.
118			167
119			Powder IR: 3417, 1641, 1620 (cm ⁻¹)
120			Powder IR: 3424, 1656, 1611, 1557 (cm ⁻¹)
121			Powder IR: 3406, 1638, 1530, 1469 (cm ⁻¹)
122			Powder IR: 3430, 1638, 1472 (cm ⁻¹)
123			Powder IR: 3416, 1630, 1540, 1469 (cm ⁻¹)

Table 14

5





		
Example		Melting point (°C), etc.
124		Powder IR: 3300, 1625, 1520 (cm ⁻¹)
125		Monohydrochloride 159-160

Table 15




		
Example		Melting point (°C)
126		148-150

Table 16

5




		
Example		Melting point (°C)
127		164-165

Table 17




			
Example	-R ¹	-R ²	Melting point (°C), etc.
128	-CH ₃	-OCH ₃	Powder IR: 3370, 1625 (cm ⁻¹)
129	-(CH ₂) ₅ CH ₃	-C(CH ₃) ₃	118-120
130	-CH(CH ₃) ₂	-C(CH ₃) ₃	142-143
131	-CH ₂ CH ₃	-C(CH ₃) ₃	148-149

Table 18

5

			
Example	-R ¹	-R ²	Melting point (°C)
132	-CH ₂ CH ₃	-C(CH ₃) ₃	137-141 (decomposed)

Example 133




Ethanol (1000 ml) was added to 97.8 g of 2-[3-(4-pyridyl-methyl)-3-(3-pyridyl)ureido]-4-methoxy-6-tert-butylphenol,

10


and after dissolving the mixture under heating. An ethanol solution (450 ml) of 71.92 g of phosphoric acid was added dropwise to the above solution. After cooling the said solution, precipitated crystals were collected by filtration, washed with ethanol and dried to give 143.1 g of colorless crude crystals. After 950 ml of acetone was added to the said crystals, and the mixture was dissolved by adding 500 ml of water while heating. After cooling the said solution, precipitated crystals were collected by filtration and dried to give 101.9 g of 2-[3-(4-pyridylmethyl)-3-(3-pyridyl)ureido]-4-methoxy-6-tert-butylphenol triphosphate (yield: 60 %, melting point: 196-198 °C).

Example 134



Ethyl acetate (4 ml) was added to 100 mg of 2-[3-(4-pyridylmethyl)-3-(3-pyridyl)ureido]-4-methoxy-6-tert-butylphenol and the mixture was heated. 94 mg of p-toluenesulfonic acid was added to the above solution. After cooling the solution, the solvent was removed under reduced pressure and the residue was crystallized from an ethanol solution to give 129 mg of 2-[3-(4-pyridylmethyl)-3-(3-pyridyl)ureido]-4-methoxy-6-tert-butylphenol di-p-toluenesulfonate (yield: 70 %, melting point: 124-128 °C).

Example 135



(1) A mixture of 25 g of tert-butoxycarbonyl hydrazine, 37 g of ethyl 6-bromohexanoate, 26 g of potassium carbonate

and 40 ml of hexamethylphosphoramide (HMPA) was stirred at room temperature for 3.5 hours. Water was added to the mixture, and the resulting mixture was extracted with ethyl acetate. The organic layer was washed and dried, and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (solvent; chloroform : ethyl acetate = 3 : 1) to give 16 g of ethyl 6-(N'-tert-butoxycarbonylhydrazino)hexanoate (state: oily product, IR: 3350, 1740, 1720 cm^{-1}).

10

(2) To 12 g of ethyl 6-(N'-tert-butoxycarbonylhydrazino)hexanoate was added 20 ml of a 15 % hydrogen chloride-dioxane solution, and the mixture was stirred at room temperature for 3 hours. Ether (diethyl ether) was added to the mixture, and precipitated crystals were collected by filtration and washed with ether to give 6.3 g of ethyl 6-hydrazinohexanoate hydrochloride (yield: 68 %, IR (KBr): 1740 cm^{-1}).

20 (3) A mixture of 19.1 ml of 2.464M phosgene-dichloromethane solution and 200 ml of dichloromethane was cooled to -78°C , and to the mixture was added dropwise a mixture of 7.04 g of (2-amino-4-methoxy-6-tert-butylphenoxy)methoxymethane, 8.9 g of triethylamine and 70 ml of dichloromethane to the above solution. The temperature of the resulting mixture was raised to 0°C and the solvent was removed under reduced pressure. To the residue was added 100 ml of dimethylformamide (DMF), and then, a mixture of 6.2 g of ethyl 6-hydrazinohexanoate hydrochloride, 7.42 g of triethylamine and 100 ml of DMF was added dropwise to the above mixture at room temperature. The resulting mixture was stirred at room temperature for 5 hours. DMF was removed under reduced pressure, and ethyl acetate was added to the residue. The mixture was washed and dried, and the solvent was removed under reduced pressure. The residue was applied to silica gel column chromatography

25
30
35


(solvent; hexane : ethyl acetate = 2 : 1) to give 5.8 g of {2-[3-(5-ethoxycarbonylpentyl)-3-aminoureido]-4-methoxy-6-tert-butylphenoxy}methoxymethane (state: oily product, IR: 3360, 1735, 1675, 1600 cm^{-1}) and 2.19 g of {2-[3-(5-ethoxycarbonylpentyl)-3-[3-(2-methoxymethoxy-3-tert-butyl-5-methoxyphenyl)ureido]ureido]-4-methoxy-6-tert-butylphenoxy}methoxymethane (state: oily product, IR: 3350, 1735, 1690, 1610, 1590 cm^{-1}), respectively.

10 (4) A mixture of 5 g of {2-[3-(5-ethoxycarbonylpentyl)-3-aminoureido]-4-methoxy-6-tert-butylphenoxy}methoxymethane, 5 g of 4-chlorobenzenesulfonyl chloride, 7.24 g of triethylamine and 20 ml of chloroform was refluxed for 4 hours. The solvent was removed under reduced pressure.
15 Ethyl acetate was added to the residue and the mixture was washed and dried, and the solvent was removed under reduced pressure to give 4 g of {2-[3-(5-ethoxycarbonylpentyl)-3-(4-chlorobenzenesulfonylamino)ureido]-4-methoxy-6-tert-butylphenoxy}methoxymethane (yield: 57 %, state: oily
20 product, IR (film): 3400, 1732, 1710, 1610, 1590 cm^{-1}).

(5) The product (1.38 g) thus obtained was dissolved in 13 ml of tetrahydrofuran (THF), and 1.3 ml of conc. hydrochloric acid was added to the solution and the mixture was
25 stirred at room temperature for 3 hours. The solvent was removed under reduced pressure. Ethyl acetate was added to the residue and the mixture was washed and dried, and then, the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography
30 (solvent; chloroform : ethyl acetate = 4 : 1) and crystallized from isopropyl ether to give 1.1 g of 2-[3-(5-ethoxycarbonylpentyl)-3-(4-chlorobenzenesulfonylamino)ureido]-4-methoxy-6-tert-butylphenol (yield: 86 %, melting point: 69-70 $^{\circ}\text{C}$).

35


Example 136



- (1) A mixture of 2.2 g of {2-[3-(5-ethoxycarbonylpentyl)-3-[3-(2-methoxymethoxy-3-tert-butyl-5-methoxyphenyl)-ureido]ureido-4-methoxy-6-tert-butylphenoxy}methoxymethane
 5 obtained in Example 135 (3), 420 mg of 85 % potassium hydroxide and 15 ml of methanol was stirred at room temperature for 3 hours. After removing methanol under reduced pressure, water and ethyl acetate was added to the residue and the mixture was acidified with 5 % hydrochloric
 10 acid. The organic layer was separated, and washed and dried. After removing the solvent under reduced pressure, the residue was purified by silica gel column chromatography (solvent; chloroform : ethyl acetate = 5 : 1) to give
 15 1.38 g of {2-[3-(5-methoxycarbonylpentyl)-3-[3-(2-methoxy-methoxy-3-tert-butyl-5-methoxyphenyl)ureido]ureido-4-methoxy-6-tert-butylphenoxy}methoxymethane (yield: 64 %, state: oily product, IR: 3350, 1740, 1690, 1610, 1590 cm⁻¹).
- 20 (2) The product (1.3 g) thus obtained was treated in the same manner as described in Example 135 (5) to give 650 mg of 2-[3-(5-methoxycarbonylpentyl)-3-[3-(2-hydroxy-3-tert-butyl-5-methoxyphenyl)ureido]ureido-4-methoxy-6-tert-butylphenol (yield: 57 %, melting point: 157-159 °C).

25


Example 137



10 % Palladium-carbon (Pd-C) (150 mg) was added to 10 ml of a methanol solution containing 500 mg of 2-[3-((1S)-5-

benzyloxycarbonylamino-1-methoxycarbonylpentyl)ureido]-4-methoxy-6-tert-butylphenol. The mixture was subjected to catalytic reduction at normal pressure for 2 hours. After removing the catalyst, the reaction mixture was condensed.
5 Methanol was added to the precipitated crystals and the crystals were collected by filtration to give 145 mg of 2-[3-((3S)-2-oxo-perhydroazepin-3-yl)ureido]-4-methoxy-6-tert-butylphenol (yield: 43 %, melting point: 178-179 °C).

10 Example 138



(1) A mixed solution of 47.9 ml of 2.901 M phosgene-dichloromethane solution and 400 ml of dichloromethane was cooled to -78 °C. To the mixture was added dropwise a
15 mixture of 22.15 g of (2-amino-4-methoxy-6-tert-butylphenoxy)methoxymethane, 38.7 ml of triethylamine and 400 ml of dichloromethane. The temperature of the mixture was raised to 0 °C, and the solvent was removed under reduced pressure. Dichloromethane (350 ml) was added to the
20 residue, and at room temperature, a mixture of 21.78 g of N-phenyl-N-(5-ethoxycarbonylpentyl)amine, 19.4 ml of triethylamine and 350 ml of dichloromethane was added dropwise. The mixture was further stirred at room temperature overnight. The reaction mixture was washed and dried, the
25 solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography (solvent; chloroform : ethyl acetate = 20 : 1) to give 27.72 g of {2-[3-phenyl-3-(5-ethoxycarbonylpentyl)ureido]-4-methoxy-6-tert-butylphenoxy)methoxymethane (yield: 60 %, state: oily
30 product, IR: 3380, 1735, 1680, 1610, 1595 cm⁻¹).

(2) A 10 % sodium hydroxide aqueous solution (55 ml) was added to 275 ml of an ethanol solution containing 27.54 g of the product thus obtained, and the mixture was stirred at room temperature for 4 hours. Under ice-cooling, the
5 reaction mixture was adjusted to pH = 1 with 10 % hydrochloric acid, and the mixture was extracted with ethyl acetate. The extract was washed and dried, and the solvent was removed under reduced pressure. The crystalline residue was recrystallized from a mixed solution of isopropyl
10 ether and ethyl acetate to give 19.85 g of {2-[3-phenyl-3-(5-carboxypentyl)ureido]-4-methoxy-6-tert-butylphenoxy}-methoxymethane (yield: 76 %, melting point: 109-111 °C).

(3) Conc. hydrochloric acid (4 ml) was added to 100 ml of
15 a tetrahydrofuran (THF) solution containing 10.0 g of the product thus obtained, and the mixture was stirred at room temperature for one hour. The solvent was removed under reduced pressure, water was added to the residue and the mixture was extracted with ethyl acetate. The extract was
20 washed and dried, and the solvent was removed under reduced pressure and the residue was recrystallized from a mixed solution of isopropyl ether and hexane to give 6.39 g of 2-[3-phenyl-3-(5-carboxypentyl)ureido]-4-methoxy-6-tert-butylphenol (yield: 70 %, melting point: 95-98 °C).

25

Examples 139 to 154

The corresponding starting materials were treated in the same manner as described in Example 138 to give the
30 compounds as shown in Table 19.

Table 19















			
Example	-R ⁵	-R ⁶	Melting point ('C), etc.
139		-(CH ₂) ₅ COOH	133-134
140		-(CH ₂) ₃ COOH	118-120
141	-CH ₂ - 	-(CH ₂) ₅ COOH	100-103
142		-(CH ₂) ₆ COOH	86-89
143		-(CH ₂) ₆ COOH	131-134
144		-(CH ₂) ₄ COOH	139-140
145		-(CH ₂) ₄ COOH	132-133
146	-(CH ₂) ₁₅ CH ₃	 -COOH	129-131
147	-(CH ₂) ₁₃ CH ₃	 -COOH	132-134
148	-(CH ₂) ₇ CH ₃	 -COOH	151-152
149		-CH ₂ COOH	156-158
150		-(CH ₂) ₃ COOH	Powder IR: 3310, 2931, 1708, 1620 (cm ⁻¹)
151	 -(CH ₂) ₇ CH ₃	-CH ₂ COOH	129-131

Table 19 (contd.)

			
Example	-R ⁵	-R ⁶	Melting point (°C), etc.
152		-(CH ₂) ₃ COOH	Powder IR: 1708, 1628, 1530, 1490 (cm ⁻¹)
153		-CH ₂ COOH	175-177
154	-H	 (S)	Powder IR: 3377, 1650, 1543 (cm ⁻¹)

Example 155



5

(1) Under ice-cooling, 2.5 g of 1,3-dicyclohexylcarbodiimide (DCC) was added to a mixture of 5.0 g of {2-[3-phenyl-3-(3-carboxypropyl)ureido]-4-methoxy-6-tert-butylphenoxy}methoxymethane, 1.4 g of N-hydroxysuccinimide (HOSu) and 50 ml of tetrahydrofuran (THF). The mixture was stirred at room temperature for 5 hours. Insoluble materials were filtered off and the filtrate was condensed. Under ice-cooling, a mixed solution of 1.2 ml of diethylamine and 10 ml of dimethylformamide (DMF) was added dropwise to a mixture of the obtained residue, 1.9 ml of triethylamine and 10 ml of DMF. The resulting mixture was stirred at room temperature overnight. Ethyl acetate was added to the reaction mixture and the mixture was washed

10

15

and dried, the solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography (solvent; chloroform : ethyl acetate = 1 : 2) to give 3.95 g of {2-[3-phenyl-3-(3-diethylaminocarbonylpropyl)ureido]-4-methoxy-6-tert-butylphenoxy}methoxymethane (yield: 70 %, state: pale yellow oily product, IR: 3340, 1676, 1635, 1590, 1519 cm^{-1}).

(2) Conc. hydrochloric acid (2 ml) was added to 30 ml of a THF solution containing 3.9 g of the product thus obtained, and the mixture was stirred at room temperature for one hour. After removing THF under reduced pressure, ethyl acetate was added to the residue and the mixture was washed and dried. The solvent was removed under reduced pressure and the residue was recrystallized from a mixed solution of isopropyl ether and ethyl acetate to give 2.86 g of 2-[3-phenyl-3-(3-diethylaminocarbonylpropyl)ureido]-4-methoxy-6-tert-butylphenol (yield: 80 %, melting point: 131-133 $^{\circ}\text{C}$).

Examples 156 to 158


The corresponding starting materials were treated in the same manner as described in Example 155 to give the compounds as shown in Table 20.

25

Table 20

Example	-R ⁵	-R ⁶	Melting point (°C)
156		$-(CH_2)_3-C(=O)-NH-CH_2CH_3$	156-158
157		$-(CH_2)_3-C(=O)-NH-CH_2CH(OH)CH_2OH$	102-105
158		$-(CH_2)_3-C(=O)-N$ (part of a morpholine ring)	129-131

Example 159




5 Under ice-cooling, 1.03 ml of ethyl chlorocarbonate was added dropwise to a mixed solution of 2.45 g of 2-[3-cycloheptyl-3-(4-dimethylaminophenyl)ureido]-4-methoxy-6-tert-butylphenol, 1.51 ml of triethylamine and 50 ml of

10 dichloromethane, and the mixture was stirred at room temperature for 2 hours. After washing and drying, the solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography (solvent; chloroform : ethyl acetate = 20 : 1), and precipitated

15 crystals were recrystallized from a mixed solution of isopropyl ether and ethyl acetate. The resulting crystals were dissolved in 50 ml of dichloromethane, and 2 ml of a

4N hydrogen chloride-dioxane solution was added thereto. The mixture was evaporated to dryness under reduced pressure. The residue was crystallized from an isopropyl ether solution to give 1.34 g of O-ethoxycarbonyl-2-[3-cycloheptyl-3-(4-dimethylaminophenyl)ureido]-4-methoxy-6-tert-butylphenol hydrochloride (yield: 44 %, melting point: 163-167 °C (decomposed)).


Example 160



10

2-[3-Cycloheptyl-3-(4-dimethylaminophenyl)ureido]-4-methoxy-6-tert-butylphenol and acetic anhydride were treated in the same manner as described in Example 159 to give O-acetyl-2-[3-cycloheptyl-3-(4-dimethylaminophenyl)-ureido]-4-methoxy-6-tert-butylphenol hydrochloride (melting point: 170-171 °C).

Example 161



20 2-[3-(3-Pyridylmethyl)ureido]-4-methoxy-6-tert-butylphenol and acetic anhydride were treated in the same manner as described in Example 159 to give O-acetyl-2-[3-(3-pyridylmethyl)ureido]-4-methoxy-6-tert-butylphenol hydrochloride (melting point: 138-142 °C).







25

Examples 162 to 166

The corresponding starting materials were treated in the same manner as described in Example 159 to give the compounds as shown in Table 21.

5




Table 21

		
Example	-R ³	Melting point (°C)
162		201-203
163		183-185
164		209-211
165		145-147
166		159-160


Examples 167 to 168

- 10 The corresponding starting materials were treated in the same manner as described in Example 159 to give the compounds as shown in Table 22.

Table 22

		
Example	-R³	Melting point (°C), etc.
167		Powder IR: 3433, 1760, 1670 (cm⁻¹)
168		118-122

Example 169




5

A mixture of 4.00 g of 2-(3-cyclohexyl-3-phenylmethyl-ureido)-4-methoxy-6-tert-butylphenol, 2.0 ml of acetic anhydride, 3.2 ml of triethylamine and 80 ml of dichloromethane was stirred at room temperature for 24 hours. The reaction mixture was washed and dried, and the solvent was removed under reduced pressure. The residue was applied to silica gel column chromatography (solvent; chloroform : ethyl acetate = 9 : 1) to give 735 mg of O-acetyl-2-(3-cyclohexyl-3-phenylmethylureido)-4-methoxy-6-tert-butylphenol (R_f=0.75, melting point: 129-132 °C (recrystallized from hexane)).


15

Example 170



By continuing separation using silica gel column chromatography of Example 169, 2.53 g of 2-(1-acetyl-3-cyclohexyl-3-phenylmethylureido)-4-methoxy-6-tert-butylphenol was
 5 obtained. (Rf=0.39, melting point: 153-155 °C (recrystallized from a mixed solution of isopropyl ether and ethyl acetate)).

Example 171



10


Under ice-cooling, 0.407 g of 62.4 % sodium hydride was added to a mixture of 4.00 g of 2-[3-cycloheptyl-3-(4-dimethylaminophenyl)ureido]-4-methoxy-6-tert-butylphenol, 1.9 ml of chloromethylpivalate and 40 ml of dimethylformamide (DMF), and the temperature of the mixture was gradually raised to room temperature. The mixture was further stirred at room temperature for 2 hours. A saturated saline solution was added to the mixture and the mixture was extracted with ethyl acetate. The extract was washed
 15 and dried, and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (solvent; hexane : ethyl acetate = 4 : 1) and precipitated crystals were recrystallized from an isopropyl ether solution. The obtained crystals were dissolved in 10
 20 ml of dichloromethane, and 5 ml of 4N hydrogen chloride-dioxane solution was added to the solution. The mixture was evaporated to dryness under reduced pressure. The

25

residue was crystallized from a diethyl ether solution to give 1.65 g of O-pivaloyloxymethyl-2-[3-cycloheptyl-3-(4-dimethylaminophenyl)ureido]-4-methoxy-6-tert-butylphenol hydrochloride (melting point: 114-118 °C (decomposed)).

5

Example 172



(1) A mixture of 1.5 g of 2-[3-cycloheptyl-3-(4-dimethylaminophenyl)ureido]-4-methoxy-6-tert-butylphenol, 2.16 g of N-benzyloxycarbonyl-L-alanine, 1.95 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (WSC), 0.62 g of 4-dimethylaminopyridine (DMPA) and 30 ml of dimethylformamide (DMF) was stirred at room temperature for 5 hours. A saturated saline solution was added to the mixture and the mixture was extracted with ethyl acetate. The extract was washed and dried. The solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography (solvent; hexane : ethyl acetate = 4 : 1) to give 1.3 g of O-(N-benzyloxycarbonyl-L-alanyl)-2-[3-cycloheptyl-3-(4-dimethylaminophenyl)ureido]-4-methoxy-6-tert-butylphenol (yield: 60 %, melting point: 126 °C).

(2) The product (800 mg) thus obtained was dissolved in 50 ml of methanol. 1 ml of conc. hydrochloric acid and 200 mg of 10 % palladium-carbon (Pd-C) were added to the solution and the mixture was subjected to medium pressure catalytic reduction by using a Parr's reduction apparatus for one hour. After removing the catalyst by filtration, the filtrate was evaporated to dryness under reduced pressure, and to the residue was added diethyl ether to give 600 mg

30







of O-(L-alanyl)-2-[3-cycloheptyl-3-(4-dimethylaminophenyl)-ureido]-4-methoxy-6-tert-butylphenol dihydrochloride as powder (yield: 83 %, IR: 3424, 1771, 1674, 1640, 1599 cm^{-1}).

5

Examples 173 to 177


The corresponding starting materials were treated in the same manner as described in Example 172 to give the
10 compounds as shown in Table 23.

Table 23

		
Example	-R³	Properties
173		Dihydrochloride Powder IR: 3450, 1775, 1645, 1601, 1510 (cm^{-1})
174		Dihydrochloride Powder IR: 3453, 1772, 1733, 1635, 1601 (cm^{-1})
175		Dihydrochloride Powder IR: 3420, 1745, 1634, 1601 (cm^{-1})
176		Trihydrochloride Powder IR: 3421, 1767, 1633, 1602 (cm^{-1})
177		Dihydrochloride Powder IR: 3420, 1764, 1650, 1599 (cm^{-1})

Example 178

5



10 (1) A mixture of 2.45 g of 2-[3-(2-cyclohexylethyl)-3-phenylureido]-4-methoxy-6-tert-butylphenol, 10.30 g of N-benzyloxycarbonyl-L-alanine, 8.81 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (WSC), 1.06 g of 4-dimethylaminopyridine (DMPA) and 50 ml of DMF was
15 stirred at room temperature for 4 hours. Then, a saturated saline solution was added to the mixture and the mixture was extracted with ethyl acetate, and the extract was washed and dried. The solvent was removed under reduced pressure and the residue was purified by silica gel column
20 chromatography (solvent; hexane : ethyl acetate = 2 : 1) to separate 1.09 g of O-(N-benzyloxycarbonyl-L-alanyl)-2-[3-(2-cyclohexylethyl)-3-phenylureido]-4-methoxy-6-tert-butylphenol (Compound A) (Rf=0.71, yield: 30 %, state: oily product, IR (film): 3325, 1726 cm⁻¹) and 1.89 g of 2-[1-(N-benzyloxycarbonyl-L-alanyl)-3-(2-cyclohexylethyl)-3-phenylureido]-4-methoxy-6-tert-butylphenol (Compound B)
25 (Rf=0.39, yield: 52 %, state: oily product, IR (film): 3319, 1710 cm⁻¹).


30 (2) To 40 ml of a methanol solution containing 1.70 g of Compound A obtained in (1) were added 1 ml of conc. hydrochloric acid and 0.75 g of 10 % palladium-carbon (Pd-C). The mixture was subjected to catalytic reduction at normal temperature under normal pressure for 2 hours. After
35 removing the catalyst by filtration, the filtrate was evaporated to dryness under reduced pressure. The residue

was crystallized by adding hexane to give 1.29 g of O-(L-alanyl)-2-[3-(2-cyclohexylethyl)-3-phenylureido]-4-methoxy-6-tert-butylphenol (yield: 90 %, state: oily product, IR: 3420, 1775, 1750, 1675, 1650, 1595 cm^{-1}).

5

Example 179

10




To 75 ml of a methanol solution containing 2.5 g of Compound B obtained in Example 178 (1) were added 1.5 ml of conc. hydrochloric acid and 1.0 g of 10 % palladium-carbon (Pd-C). The mixture was subjected to catalytic reduction at normal temperature under normal pressure for 2 hours. After removing the catalyst by filtration, the filtrate was evaporated to dryness under reduced pressure, and the residue was crystallized by adding hexane to give 1.80 g of 2-[1-L-alanyl-3-(2-cyclohexylethyl)-3-phenylureido]-4-methoxy-6-tert-butylphenol (yield: 85 %, state: powder, IR: 3500 (br), 1730, 1705 cm^{-1}).

25

Examples 180 and 181

2-[3-(2-Cyclohexylethyl)-3-phenylureido]-4-methoxy-6-tert-butylphenol, N-benzyloxycarbonylglycine and others were treated in the same manner as described in Examples 178 and 179 to give the following compounds.

35




(Example 180)

O-Glycyl-2-[3-(2-cyclohexylethyl)-3-phenylureido]-4-methoxy-6-tert-butylphenol hydrochloride

IR: 3450, 1778, 1690, 1594 cm^{-1}

5



10

(Example 181)


2-[1-Glycyl-3-(2-cyclohexylethyl)-3-phenylureido]-4-methoxy-6-tert-butylphenol hydrochloride

IR: 3480 (br), 1699, 1596 cm^{-1}

15

Example 182

20



(1) 2-[3-Cycloheptyl-3-(4-dimethylaminophenyl)ureido]-4-methoxy-6-tert-butylphenol and N-benzyloxycarbonylglycine were treated in the same manner as described in Example 172 (1) to give O-(N-benzyloxycarbonylglycyl)-2-[3-cycloheptyl-3-(4-dimethylaminophenyl)ureido]-4-methoxy-6-tert-butylphenol.

30


(2) Triethylamine (0.42 ml) was added to a 6 ml of DMF solution containing 646 mg of the product thus obtained, and the mixture was stirred at room temperature overnight. Water was added to the mixture, and the mixture was extracted with ethyl acetate. The extract was washed and dried, and the solvent was removed under reduced pressure.

35

To 30 ml of a methanol solution containing the thus obtained residue were added 0.3 ml of conc. hydrochloric acid and 100 mg of 10 % palladium-carbon (Pd-C). The mixture was subjected to catalytic reduction by using a Parr's reduction apparatus for one hour. After removing the catalyst by filtration, the filtrate was evaporated to dryness under reduced pressure. Diethyl ether was added to the residue to give 351 mg of 2-[1-glycyl-3-cycloheptyl-3-(4-dimethylaminophenyl)ureido]-4-methoxy-6-tert-butylphenol dihydrochloride as powder (yield: 60 %, IR: 3450 (br), 1711, 1607, 1511 cm^{-1}).

Example 183

15




20 (1) A 10 % sodium hydroxide aqueous solution (8.8 ml) was added to 2.16 g of 3-aminomethylpyridine, then, 1.8 ml of carbon disulfide was added dropwise to the mixture at room temperature and the mixture was stirred at room temperature for one hour. Under ice-cooling, 2.39 g of ethyl chloro-
25 carbonate was added dropwise to the mixture and the resulting mixture was stirred at room temperature for one hour. Water was added to the mixture, and the mixture was extracted with ethyl acetate. The extract was washed and dried, and the solvent was removed under reduced pressure.
30 To the obtained residue were added 4.79 g of 2-amino-4-methoxy-6-tert-butylphenoxy)methoxymethane and 20 ml of toluene. After refluxing the mixture for one hour, water was added to the mixture and the mixture was extracted with ethyl acetate. The extract was washed and dried, and the
35 solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (solvent;

ethyl acetate) and recrystallized from a mixed solution of isopropyl ether and ethyl acetate to give 3.85 g of {2-[3-(3-pyridylmethyl)thioureido]-4-methoxy-6-tert-butylphenoxy}methoxymethane (yield: 49 %, melting point: 137-138 °C).

(2) A mixture of 2.5 g of the product thus obtained, 50 ml of 14.5 % ammonia-methanol solution and 2.5 g of copper sulfate pentahydrate was vigorously stirred at 40 °C for 3 hours. Insoluble materials were removed from the mixture by filtration, and after condensing the filtrate, the residue was purified by silica gel column chromatography (solvent; chloroform : ethanol = 2 : 1) to give 2.11 g of {2-[3-(3-pyridylmethylguanidino)-4-methoxy-6-tert-butylphenoxy}methoxymethane (yield: 88 %, melting point: 103-108 °C).

(3) After stirring a mixture of 2.07 g of the product thus obtained, 3 ml of conc. hydrochloric acid and 35 ml of methanol at room temperature for 2 hours, the mixture was evaporated to dryness under reduced pressure. The residue was crystallized from an ethyl acetate solution. The crystals were further recrystallized from a mixed solution of ethyl acetate and ethanol to give 1.90 g of 2-[3-(3-pyridylmethyl)guanidino]-4-methoxy-6-tert-butylphenol dihydrochloride (yield: 85 %, melting point: 160-165 °C).

Example 184




35 (1) {2-[3-(3-Pyridylmethyl)thioureido]-4-methoxy-6-tert-butylphenoxy}methoxymethane and methylamine were treated in

the same manner as described in Example 183 (2) to give {2-[2-methyl-3-(3-pyridylmethyl)guanidino]-4-methoxy-6-tert-butylphenoxy}methoxymethane as oily product.

- 5 (2) The product thus obtained was treated in the same manner as described in Example 183 (3) to give 2-[2-methyl-3-(3-pyridylmethyl)guanidino]-4-methoxy-6-tert-butylphenol dihydrochloride (melting point: 158-161 °C).

10 Example 185




- (1) A dichloromethane (170 ml) solution containing 2.97 g of triphosgene was cooled to -78 °C, and a mixture of 5.98 g of (2-amino-4-methoxy-6-tert-butylphenoxy)methoxymethane, 15 6.97 ml of triethylamine and 80 ml of dichloromethane was added dropwise to the solution. The temperature of the mixture was raised to 0 °C, and the solvent was removed under reduced pressure to give a residue.
- 20 On the other hand, 170 ml of a THF solution containing 5.00 g of tert-butyl (4S)-1-methyl-2-oxoimidazolidine-4-carboxylate was cooled to -78 °C, and 2.95 g of potassium tert-butoxide was added to the solution. After raising the temperature to -30 °C, the mixture was cooled again to -78 25 °C, and 80 ml of a THF solution containing the residue obtained above was gradually poured to the mixture. The resulting mixture was stirred at the same temperature for 30 minutes, and the reaction mixture was added to a mixed solution of 150 ml of ethyl acetate, 1.5 ml of acetic acid 30 and 150 ml of a saturated saline solution. The organic layer was separated and the remaining aqueous layer was extracted with ethyl acetate. The organic layer and the extract were combined. The mixture was washed and dried,

and the solvent was removed under reduced pressure. The residue was recrystallized from an isopropyl ether solution to give 8.43 g of {2-[(4S)-2-oxo-1-methyl-4-tert-butoxycarbonylimidazolidin-3-ylamido]-4-methoxy-6-tert-butylphenoxy}methoxymethane (yield: 72 %, melting point: 133-134 °C).


(2) A mixture of 3.03 g of the product thus obtained, 0.5 ml of conc. hydrochloric acid and 60 ml of methanol was stirred at room temperature for 2 hours. The mixture was evaporated to dryness under reduced pressure and the residue was purified by silica gel column chromatography (solvent; hexane : ethyl acetate = 1 : 1) and recrystallized from isopropyl ether to give 1.49 g of 2-[(4S)-2-oxo-1-methyl-4-tert-butoxycarbonylimidazolidin-3-ylamido]-4-methoxy-6-tert-butylphenol (yield: 54 %, melting point: 123-124 °C).

Example 186



A mixture of 624 mg of the product obtained in Example 185 and 6 ml of trifluoroacetic acid was stirred at room temperature for one hour, and the mixture was evaporated to dryness under reduced pressure. Toluene was added to the residue and the mixture was again evaporated to dryness under reduced pressure, and the residue was crystallized from an isopropyl ether solution to give 258 mg of 2-[(4S)-2-oxo-1-methyl-4-carboxylimidazolidin-3-ylamido]-4-methoxy-6-tert-butylphenol (yield: 48 %, melting point: 102-104 °C).

Example 187



5

(1) Triethylamine (13.3 ml) was added dropwise to a mixture of 5 g of bis(2-hydroxyethyl)amine, 14.3 g of tert-butyl-dimethylsilyl chloride and 100 ml of dimethylformamide (DMF). A catalytic amount of 4-dimethylaminopyridine was added to the mixture and the resulting mixture was stirred for 5 hours. Then, the mixture was diluted with ethyl acetate. The diluted mixture was washed and dried, and the solvent was removed under reduced pressure. To the obtained residue were added 10.6 g of 3-(N-benzyloxycarbonylamino)-propionic acid, 7.1 g of 1-hydroxybenzotriazole and 100 ml of DMF, and under ice-cooling, 10.8 g of 1,3-dicyclohexylcarbodiimide (DCC) was added to the mixture. The resulting mixture was stirred at room temperature overnight. The mixture was diluted with ethyl acetate, and insoluble materials were removed from the mixture by filtration. The filtrate was washed and dried, and the solvent was removed under reduced pressure. The residue was applied to silica gel column chromatography (solvent; hexane : ethyl acetate = 4 : 1). The condensed eluate was dissolved in 200 ml of methanol, and 1 g of 10 % palladium-carbon (Pd-C) was added to the solution. The mixture was subjected to catalytic reduction at normal temperature under normal pressure for 0.5 hour. The catalyst was filtered off, and the filtrate was condensed to give 11.4 g of {2-[bis(2-tert-butyl dimethylsilyloxyethyl)amino]carbonyl ethyl}amine (yield: 59 %) as a colorless oily product.


(2) The product thus obtained was treated in the same manner as described in Example 16 (1) to give {2-[3-[2-[bis(2-tert-butyl dimethylsilyloxyethyl)aminocarbonyl]-

ethyl]ureido]-4-methoxy-6-tert-butylphenoxy}methoxymethane
(yield: 71 %, IR (film): 3361, 1648 cm^{-1}).

(3) To a mixed solution of 3.196 g of the product thus
5 obtained and 50 ml of THF was added 14 ml of a THF solution
containing 1M tetrabutylammonium fluoride, and the mixture
was stirred at room temperature for one hour. THF was
removed under reduced pressure and ethyl acetate was added
to the residue. The mixture was washed and dried, and then
10 the solvent was removed under reduced pressure. The
residue was purified by silica gel column chromatography
(solvent; chloroform : methanol = 9 : 1) to give 0.926 g of
{2-[3-[2-[bis(2-hydroxyethyl)aminocarbonyl]ethyl]ureido]-4-
methoxy-6-tert-butylphenoxy}methoxymethane (yield: 44 %, IR
15 (KBr): 3407, 1676, 1614
 cm^{-1}).

(4) A mixture of 843 mg of the product thus obtained, 0.5
ml of conc. hydrochloric acid and 10 ml of methanol was
20 stirred at room temperature for one hour. Methanol was
removed under reduced pressure, ethyl acetate was added to
the residue and the mixture was washed and dried. The
solvent was removed under reduced pressure and the residue
was purified by silica gel column chromatography (solvent;
25 chloroform : methanol = 9 : 1) to give 385 mg of 2-{3-[2-
[bis(2-hydroxyethyl)aminocarbonyl]ethyl]ureido)-4-methoxy-
6-tert-butylphenol (yield: 51 %, IR (film): 3344, 1615
 cm^{-1}).

30 Example 188




(1) (2-Amino-4-methoxy-6-tert-butylphenoxy)methoxymethane, phosgene and L-phenylalanine methyl ester were treated in the same manner as described in Example 16 (1) to give {2-[3-((1S)-1-methoxycarbonyl-2-phenylethyl)ureido]-4-methoxy-6-tert-butylphenoxy}methoxymethane.

(2) To a refluxed solution of 4.00 g of the product thus obtained, 851 mg of sodium borohydride and 48 ml of THF was gradually added dropwise a mixture of 7.2 ml of methanol and 8 ml of THF. The mixture was further refluxed for one hour. After cooling, water was added and the mixture was extracted with dichloromethane. The extract was washed and dried. The solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography (solvent; ethyl acetate) to give 3.674 g of {2-[3-((1S)-1-hydroxymethyl-2-phenylethyl)ureido]-4-methoxy-6-tert-butylphenoxy}methoxymethane (yield: 98 %, IR: 3350, 1650, 1551 cm^{-1}).

(3) The product thus obtained was treated in the same manner as described in Example 16 (2) to give 2-[3-((1S)-1-hydroxymethyl-2-phenylethyl)ureido]-4-methoxy-6-tert-butylphenol (IR: 3356, 1645, 1558 cm^{-1}).

Example 189




To a mixture of 680 mg of 2-[[4-(4-nitrophenyl)piperazin-1-yl]carbonylamino]-4-methoxy-6-tert-butylphenol hydrochloride, 30 ml of methanol and 30 ml of dioxane was added 100 mg of 10 % palladium-carbon (Pd-C). The mixture was subjected to catalytic reduction for 4 hours by using a Parr's reduction apparatus. After removing the catalyst by filtration, the filtrate was condensed. The residue was

dissolved in 10 ml of dichloromethane, and after adding 1 ml of 4N hydrogen chloride-dioxane solution, the mixture was treated with an activated charcoal. The treated mixture was evaporated to dryness under reduced pressure to give 210 mg of 2-([4-(4-aminophenyl)piperazin-1-yl]carbon-ylamino)-4-methoxy-6-tert-butylphenol dihydrochloride as powder.

Example 190

10




15

To a mixed solution comprising 1 g of 2-[3-((1S)-5-benzyl-oxycarbonylamino-1-methoxycarbonylpentyl)ureido]-4-methoxy-6-tert-butylphenol and 30 ml of methanol were added 0.5 ml of conc. hydrochloric acid and 200 mg of 10 % palladium-carbon (Pd-C). The mixture was subjected to catalytic reduction at normal temperature under normal pressure for one hour. After removing the catalyst, the filtrate was condensed. Hexane was added to the residue to give 685 mg of 2-[3-((1S)-5-amino-1-methoxycarbonylpentyl)ureido]-4-methoxy-6-tert-butylphenol hydrochloride (yield: 85 %, state: yellow powder, IR: 3300 (br), 1725, 1650, 1560 cm^{-1}).

25

Example 191

30




35

4N hydrogen chloride-dioxane solution (15 ml) was added to 1.50 g of 2-[3-(1-tert-butoxycarbonylpiperidin-4-yl)methyl-


3-phenylmethylureido]-4-methoxy-6-tert-butylphenol, and the mixture was stirred at room temperature for 2 hours. Then, the mixture was evaporated to dryness under reduced pressure and the residue was recrystallized from an ethanol solution to give 0.912 g of 2-[3-(4-piperidylmethyl)-3-phenylmethylureido]-4-methoxy-6-tert-butylphenol hydrochloride (yield: 69 %, melting point: 195-196 °C).

Example 192



2-[3-(4-tert-Butoxycarbonylamino-cyclohexyl)-3-phenylmethylureido]-4-methoxy-6-tert-butylphenol was treated in the same manner as described in Example 191 to give 2-[3-(4-aminocyclohexyl)-3-phenylmethylureido]-4-methoxy-6-tert-butylphenol hydrochloride (IR: 3400, 1626 cm^{-1}).


Example 193



2-[3-(4-tert-Butoxycarbonylamino-phenyl)-3-cycloheptylureido]-4-methoxy-6-tert-butylphenol was treated in the same manner as described in Example 191 to give 2-[3-(4-aminophenyl)-3-cycloheptylureido]-4-methoxy-6-tert-butylphenol hydrochloride (melting point: 156-157 °C).

Example 194


5



10 2-[3-(1-tert-Butoxycarbonylpiperidin-4-ylmethyl)-3-(3-pyridylmethyl)ureido]-4-methoxy-6-tert-butylphenol was treated in the same manner as described in Example 191 to give 2-[3-(4-piperidylmethyl)-3-(3-pyridylmethyl)ureido]-4-methoxy-6-tert-butylphenol dihydrochloride (IR: 3418, 1630, 1530, 1471 cm^{-1}).

Example 195

20



(1) (2-Amino-4-methoxy-6-tert-butylphenoxy)methoxymethane, N-phenyl-N-(4-benzyloxycarbonylaminocyclohexyl)amine and triphosgene were treated in the same manner as described in Example 53 to give {2-[3-phenyl-3-(4-benzyloxycarbonylaminocyclohexyl)ureido]-4-methoxy-6-tert-butylphenoxy}-methoxymethane (melting point: 145-154 $^{\circ}\text{C}$).

30 (2) To a mixed solution comprising 2.192 g of the product thus obtained and 300 ml of methanol was added 1 g of 10 % palladium-carbon (Pd-C). The mixture was subjected to catalytic reduction at normal temperature under normal pressure for 3 hours. After removing the catalyst by filtration, the filtrate was condensed to give {2-[3-phenyl-3-(4-aminocyclohexyl)ureido]-4-methoxy-6-tert-

butylphenoxy}methoxymethane (yield: 98 %, IR: 3400, 1667, 1594, 1519 cm^{-1}).

(3) The product thus obtained was treated in the same
5 manner as described in Example 53 (2) to give 2-[3-phenyl-
3-(4-aminocyclohexyl)ureido]-4-methoxy-6-tert-butylphenol
hydrochloride (state: powder, IR: 3390, 1636, 1520 cm^{-1}).

Examples 196 to 256

10

The corresponding starting materials are treated in the
same manner as described in any of the above-mentioned
Examples to give the compounds as shown in Table 24.

Table 24











		
Example		Melting point (°C), etc.
196		Powder IR: 3264, 1655, 1610, 1559 (cm ⁻¹)
197		Powder IR: 3356, 1629 (cm ⁻¹)
198		90-95
199		137-140
200		174-176
201		150-152
202		Dihydrochloride
203		Dihydrochloride

Table 24 (contd.)










		
Example	$\begin{array}{c} R^5 \\ \\ -N-R^6 \end{array}$	Melting point (°C), etc.
204		Dihydrochloride
205		Dihydrochloride
206		Dihydrochloride
207		Dihydrochloride
208		Dihydrochloride
209		Dihydrochloride
210		Dihydrochloride
211		Dihydrochloride

Table 24 (contd.)










		
Example		Melting point (°C), etc.
212		Dihydrochloride
213		Trihydrochloride
214		Trihydrochloride
215		Hydrochloride
216		Hydrochloride
217		Dihydrochloride
218		Dihydrochloride
219		Dihydrochloride

Table 24 (contd.)











		
Example		Melting point ('C), etc.
220		Dihydrochloride
221		194-196 (decomposed)
222		Powder IR: 3303, 1673, 1625, 1552 (cm ⁻¹)
223		163-166
224		148-150
225		176-177
226		Powder IR: 3400, 1642, 1471 (cm ⁻¹)
227		165-168

Table 24 (contd.)










		
Example		Melting point (°C), etc.
228		Hydrochloride
229		Dihydrochloride
230		Dihydrochloride
231		Hydrochloride
232		Dihydrochloride
233		Dihydrochloride
234		Dihydrochloride
235		Dihydrochloride

Table 24 (contd.)







		
Example	$\begin{array}{c} R^5 \\ \\ -N-R^6 \end{array}$	Melting point (°C), etc.
236		Hydrochloride
237		Hydrochloride
238		Dihydrochloride
239		Trihydrochloride
240		Dihydrochloride

Table 24 (contd.)

Example	-R ⁴	-N(R ⁵)(R ⁶)	Melting point (°C), etc.
241	-CH ₃		Dihydrochloride
242			Dihydrochloride

Table 24 (contd.)

5

Example	-N(R ⁵)(R ⁶)	Melting point (°C), etc.
243		Dihydrochloride
244		Dihydrochloride

Table 24 (contd.)












		
Example		Melting point (°C), etc.
245		Dihydrochloride
246		Dihydrochloride
247		Dihydrochloride
248		Dihydrochloride
249		Dihydrochloride
250		Dihydrochloride
251		Dihydrochloride
252		Dihydrochloride

Table 24 (contd.)

Example	$\begin{array}{c} R^5 \\ \\ -N-R^6 \end{array}$	Melting point (°C), etc.
253		Dihydrochloride
254		Dihydrochloride
255		Dihydrochloride
256		Dihydrochloride

Example 257

5



- 10 (2-Amino-4,5,6-trimethoxyphenoxy)methoxymethane was treated in the same manner as described in Example 1 to give 2-(3-phenylureido)-4,5,6-trimethoxyphenol (melting point: 123-125 °C).

Reference example 1

(1) p-Anisidine (257 g) was dissolved in 514 ml of conc. hydrochloric acid, and under ice-cooling, 1530 ml of an aqueous solution containing 158 g of sodium nitrite was added dropwise to the solution. This mixture was added dropwise under ice-cooling to 3000 ml of an aqueous solution containing 356 g of 4-methoxy-2-tert-butylphenol and 416 g of sodium hydroxide. The resulting mixture was stirred at the same temperature for 15 minutes. Conc. hydrochloric acid (about 400 ml) was added dropwise to the reaction mixture to adjust pH of the mixture to 3, and the precipitated crystals were collected by filtration. The crystals were washed and dried, and recrystallized from a mixed solution of chloroform and ethanol to give 400 g of 2-(4-methoxyphenylazo)-4-methoxy-6-tert-butylphenol (yield: 64 %, melting point: 125-127 °C, IR: 1600 cm⁻¹).

(2) To a suspension of 63 g of 62.5 % sodium hydride and 2500 ml of dimethylformamide (DMF) was added dropwise under ice-cooling 3000 ml of a tetrahydrofuran (THF) solution containing 472 g of 2-(4-methoxyphenylazo)-4-methoxy-6-tert-butylphenol. After elevating the temperature to room temperature, the mixture was ice-cooled again, and 133 g of methoxymethyl chloride was added dropwise. After stirring at room temperature for 2 hours, 300 ml of an aqueous saturated ammonium chloride solution was gradually added dropwise to the mixture. THF was removed under reduced pressure, and a saturated saline solution was added to the residue. The mixture was extracted with ethyl acetate. The extract was washed and dried, and the solvent was removed under reduced pressure. The precipitated crystals were recrystallized from a mixed solution of hexane and ethyl acetate to give 520 g of [2-(4-methoxyphenylazo)-4-methoxy-6-tert-butylphenoxy]methoxymethane (yield: 97 %, melting point: 102-103 °C, IR: 1610 cm⁻¹).

(3) To 1200 ml of a methanol solution containing 180 g of the product thus obtained was added 3 g of 10 % palladium-carbon (Pd-C). The mixture was subjected to catalytic reduction at room temperature for 30 minutes by using a Parr's reduction apparatus. After removing the catalyst by filtration, the filtrate was evaporated to dryness under reduced pressure. The obtained residue was evaporated under reduced pressure to give 109 g of (2-amino-4-methoxy-6-tert-butylphenoxy)methoxymethane (yield: 91 %, boiling point: 125-130 °C (1 mmHg), IR: 3480, 3390, 1630, 1600 cm^{-1}).

Reference example 2

(1) To a mixed solution comprising 8.6 g of 2,4-dimethoxyphenol and 80 ml of carbon disulfide (CS_2) was added dropwise 2.86 ml of bromine at 10 to 15 °C. After stirring the mixture at room temperature for one hour, water was added to the reaction mixture and the reaction mixture was extracted with diethyl ether. The extract was washed and dried, and the solvent was removed under reduced pressure. Hexane was added to the obtained residue and the precipitated crystals were collected by filtration to give 12.0 g of 3-bromo-4,6-dimethoxyphenol (yield: 92 %, melting point: 78-80 °C).

(2) A mixed solution of 12 g of the product thus obtained and 20 ml of dimethylformamide (DMF) was added dropwise to a suspension of 100 ml of DMF containing 2.5 g of 60 % sodium hydride under ice-cooling. After stirring the mixture at room temperature for 30 minutes, 4.7 ml of methoxymethyl chloride was added dropwise to the mixture and the resulting mixture was stirred at room temperature for 17 hours. DMF was removed from the reaction mixture and water was added to the residue. The mixture was

extracted with diethyl ether. The extract was washed and dried, and the solvent was removed under reduced pressure. The residue was applied to silica gel column chromatography (solvent; hexane : ethyl acetate = 4 : 1) to give 14 g of
5 (3-bromo-4,6-dimethoxyphenoxy)methoxymethane as oily product.

(3) A tetrahydrofuran (THF) solution (100 ml) of the oily product thus obtained was cooled to -78 °C, 24.2 ml of 2.5M
10 n-butyl lithium-hexane solution was added to the solution and the mixture was stirred at the same temperature for 45 minutes. To the mixture was added dropwise a mixed solution of 10 g of tosyl azide and 20 ml of THF at the same temperature, and the mixture was further stirred for 3
15 hours. To the mixture was added 170 ml of 0.3M aqueous sodium pyrophosphate ($\text{Na}_4\text{P}_2\text{O}_7$) solution. The resulting mixture was stirred at 0 to 5 °C for 2 hours and then at room temperature overnight. Insoluble materials were removed from the mixture by filtration and the filtrate was
20 extracted with diethyl ether. The extract was washed and dried, and the solvent was removed under reduced pressure. The residue was applied to silica gel column chromatography (solvent; hexane : ethyl acetate = 4 : 1) to give 9.1 g of (3-azido-4,6-dimethoxyphenoxy)methoxymethane.

25

(4) The product thus obtained was dissolved in 100 ml of tetrahydrofuran (THF), and under ice-cooling, 114 ml of 1M lithium aluminum hydride-diethyl ether solution was added dropwise to the solution. After stirring the mixture at
30 the same temperature for 2 hours, 4.3 ml of water, 4.3 ml of a 15 % aqueous sodium hydroxide solution and 12.9 ml of water were successively added dropwise to the mixture. After removing insoluble materials by filtration, the filtrate was extracted with ethyl acetate, and the extract
35 was washed and dried. The solvent was removed from the extract under reduced pressure and the residue was purified

by silica gel column chromatography (solvent; hexane : ethyl acetate = 1 : 1) to give 5.8 g of (3-amino-4,6-dimethoxyphenoxy)methoxymethane (yield: 53 %, oily product, IR: 3450, 3350 cm^{-1}).

5

Reference example 3

(1) Conc. sulfuric acid (0.4 ml) was added to a mixed solution comprising 3.3 g of 2,4-dimethoxybenzaldehyde and 30 ml of methanol, and under ice-cooling, 2.93 ml of 30 % hydrogen peroxide aqueous solution was added to the mixture. After stirring at room temperature for 4 hours, a 5 % aqueous potassium hydrogen sulfite solution was added to the mixture and the solvent was removed under reduced pressure. The residue was extracted with diethyl ether, the extract was washed and dried and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (solvent; hexane : ethyl acetate = 4 : 1) to give 2.1 g of 2,4-dimethoxyphenol (yield: 69 %, state: colorless oily product).

(2) The product (3.1 g) thus obtained was treated in the same manner as described in Reference example 1 (2) to give 3.6 g of 2,4-dimethoxyphenoxy-methoxymethane (yield: 90 %, colorless oily product).

(3) A mixed solution of 3.6 g of the product thus obtained and 50 ml of tetrahydrofuran (THF) was cooled to -78°C , and 21.6 ml of a 2M sec-butyl lithium-cyclohexane solution was added dropwise to the mixture. The mixture was further stirred for one hour. A mixed solution of 3.6 g of tosyl azide and 10 ml of THF was added dropwise to the mixture and the resulting mixture was stirred for 2 hours. The mixture was poured into 60.5 ml of 0.3M aqueous sodium pyrophosphate ($\text{Na}_4\text{P}_2\text{O}_7$) solution, and the resulting mixture was stirred under ice-cooling for 3 hours. The reaction

mixture was extracted with diethyl ether. The extract was washed and dried and the solvent was removed under reduced pressure. The residue was applied to short silica gel column chromatography (solvent; hexane : ethyl acetate = 4 : 1). The eluate was condensed and the residue was dissolved in 30 ml of THF. Under ice-cooling, 29 ml of 1M lithium aluminum hydride-diethyl ether solution was added dropwise to the solution. After stirring the mixture at the same temperature for 2 hours, 1.1 ml of water, 1.1 ml of a 15 % sodium hydroxide aqueous solution and 3.3 ml of water were successively added dropwise to the mixture. After removing insoluble materials by filtration, diethyl ether was added to the filtrate and the mixture was dried, and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (solvent; hexane : ethyl acetate = 4 : 1) to give 1.25 g of (2-amino-4,6-dimethoxyphenoxy)methoxymethane (yield: 32 %, oily product).

20 Reference example 4

(1) To a mixed solution of 25 g of 3-methoxyphenol and 100 ml of carbon disulfide (CS₂) was added dropwise 10.3 ml of bromine at room temperature. After stirring the mixture for 30 minutes, the solvent was removed under reduced pressure, and water was added to the residue. The reaction mixture was extracted with diethyl ether. The extract was washed and dried, and the solvent was removed under reduced pressure to give 34.8 g of 2-bromo-5-methoxyphenol (yield: 85 %, boiling point: 96-98 °C (4 mmHg), colorless oily product).

(2) The product (20.3 g) thus obtained was added to a suspension of 100 ml of dimethylformamide (DMF) and 4.3 g of 62 % sodium hydride, and the mixture was stirred at room temperature for 30 minutes. Then, 20 ml of octyl bromide

was added to the mixture and the mixture was further stirred at room temperature for 3 days. DMF was removed from the reaction mixture under reduced pressure, and water was added to the residue. The mixture was extracted with
5 diethyl ether. The extract was washed and dried, and the solvent was removed under reduced pressure. The residue was evaporated under reduced pressure to give 25.3 g of 2-octyloxy-4-methoxy-bromobenzene (yield: 80 %, boiling point: 160-165 °C (3 mmHg), colorless oily product).

10

(3) A mixed solution of 25.3 g of the product thus obtained and 100 ml of tetrahydrofuran (THF) was cooled to -50 °C or lower. 38.5 ml of 2.5M n-butyl lithium-hexane solution was added to the solution and the mixture was
15 stirred at the same temperature for 45 minutes. To the mixture was added dropwise a mixed solution of 7.45 ml of dimethylformamide (DMF) and 10 ml of THF, and the mixture was stirred at the same temperature for 10 minutes. Then, 10 % acetic acid was added to the mixture and the solvent
20 was removed under reduced pressure. The residue was extracted with diethyl ether. The extract was washed and dried, and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (solvent; hexane : ethyl acetate = 9 : 1) to give
25 15.8 g of 2-octyloxy-4-methoxybenzaldehyde (yield: 74 %, melting point: 37-39 °C).

(4) The product (19.8 g) thus obtained was treated in the same manner as described in Reference example 3 (1) to give
30 17.1 g of 2-octyloxy-4-methoxyphenol (yield: 90 %, melting point: 36-38 °C).

(5) The product (10 g) thus obtained was treated in the same manner as described in Reference example 1 (2) to give
35 10.5 g of (2-octyloxy-4-methoxyphenoxy)methoxymethane (yield: 89 %, colorless oily product).

(6) The product (10.5 g) thus obtained was treated in the same manner as described in Reference example 3 (3) to give 4.0 g of (2-amino-6-octyloxy-4-methoxyphenoxy)methoxymethane (yield: 36 %, melting point: 59-61 °C).

5

Reference example 5

Corresponding starting compound was treated in the same manner as described in Reference example 4 to give (2-
10 amino-6-tetradecyloxy-4-methoxyphenoxy)methoxymethane (melting point: 66-67 °C).

Reference example 6

15 (1) A mixed solution of 15.2 g of 2-methoxy-4-formyl-phenol, 26 ml of diisopropyl ethylamine, 9 ml of methoxymethyl chloride and 100 ml of tetrahydrofuran (THF) was stirred at room temperature for 3.5 hours. The solvent was removed under reduced pressure. Water was added to the
20 residue and the mixture was extracted with ethyl acetate. The extract was washed and dried, and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (solvent; hexane : ethyl acetate = 4 : 1) to give 18.9 g of (4-formyl-2-
25 methoxyphenoxy)methoxymethane (yield: 96 %, melting point: 34-37 °C).

(2) A mixture of 18.9 g of the product thus obtained, 25 g of 3-chloroperbenzoic acid (mCPBA) and 500 ml of dichloromethane was stirred under heating for 8 hours. After
30 cooling, the reaction mixture was washed and dried. The solvent was removed under reduced pressure and the obtained residue was dissolved in 200 ml of methanol. 30 ml of an aqueous solution containing 6.5 g of 85 % potassium
35 hydroxide was added dropwise to the solution. The mixture was extracted with ethyl acetate. The extract was washed

and dried and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (solvent; hexane : ethyl acetate = 4 : 1) to give 13 g of (4-hydroxy-2-methoxyphenoxy)methoxymethane
5 (yield: 73 %, melting point: 70-72 °C).

(3) The product (6.5 g) thus obtained was treated in the same manner as described in Reference example 4 (2), and the obtained residue was purified by silica gel column
10 chromatography (solvent; hexane : ethyl acetate = 4 : 1) to give 9.6 g of (4-octyloxy-2-methoxyphenoxy)methoxymethane (yield: 92 %, colorless oily product).

(4) The product (9.6 g) thus obtained was treated in the same manner as described in Reference example 3 (3) to give
15 6.7 g of (2-amino-4-octyloxy-6-methoxyphenoxy)methoxymethane (yield: 66 %, melting point: 56-57 °C).

Reference example 7

20 Corresponding starting compound was treated in the same manner as described in Reference example 6 to give (2-amino-4-hexadecyloxy-6-methoxyphenoxy)methoxymethane (IR: 3450, 3350 cm^{-1}).

25

Reference example 8

(1) 4-Methoxyphenol (124.14 g) was treated in the same manner as described in Reference example 4 (1) to give 161
30 g of 2-bromo-4-methoxyphenol (yield: 79 %, melting point: 37-38 °C).

(2) After treating 48.93 g of the product thus obtained in the same manner as described in Reference example 1 (2),
35 the resulting material was evaporated under reduced pressure to give 50.583 g of (2-bromo-4-methoxyphenoxy)-

methoxymethane (yield: 85 %, boiling point: 100 °C (2 mmHg), colorless oily product).

(3) A mixed solution of 12.1 g of the product thus
5 obtained and 60 ml of THF was cooled to -60 to -50 °C, and
20.5 ml of 2.5M n-butyl lithium-hexane solution was added
dropwise to the solution. The mixture was stirred at the
same temperature for 30 minutes, and 14.088 g of octyl
10 iodide was added dropwise to the mixture. After stirring
the mixture at room temperature overnight, water was added
to the reaction mixture and the mixture was extracted with
diethyl ether. The extract was washed, dried and con-
densed, and then evaporated under reduced pressure to give
8.238 g of (4-methoxy-2-octylphenoxy)methoxymethane (yield:
15 60 %, boiling point: 155-160 °C (2 mmHg), colorless oily
product).

(4) To a mixed solution of 8.238 g of the product thus
obtained and 73 ml of THF was added dropwise at -60 to -70
20 °C 42.6 ml of 0.76M sec-butyl lithium-cyclohexane solution.
After stirring the mixture at the same temperature for 1.5
hours, 8.09 g of diphenylphosphoryl azide (DPPA) was added
dropwise and the mixture was further stirred for 2 hours.
At the same temperature, 36.2 ml of a 70 % sodium bis(2-
25 methoxyethoxy)aluminum hydride-toluene solution was added
dropwise to the mixture and the resulting mixture was
stirred at 0 °C for one hour and then at room temperature
for 30 minutes. Ice water was added to the reaction
mixture and insoluble materials were removed by filtration
30 from the mixture. The filtrate was extracted with diethyl
ether. The extract was washed and dried, and the solvent
was removed under reduced pressure. The residue was
purified by silica gel column chromatography (solvent;
hexane : ethyl acetate = 4 : 1) to give 5.07 g of (2-amino-
35 4-methoxy-6-octylphenoxy)methoxymethane (yield: 58 %, oily
product, IR: 3450, 3350, 1605 cm⁻¹).

Reference examples 9 to 11

Corresponding starting materials were treated in the same manner as described in Reference example 8 to give the following compounds.

(Reference example 9)

(2-Amino-4-methoxy-6-methylphenoxy)methoxymethane
oily product

10 NMR (δ ppm, CDCl_3): 2.20 (3H, s), 3.55 (3H, s), 3.67 (3H, s), 3.83 (2H, s), 4.90 (2H, s), 6.12 (2H, s)

(Reference example 10)

(2-Amino-4-methoxy-6-ethylphenoxy)methoxymethane
15 oily product

NMR (δ ppm, CDCl_3): 1.20 (3H, t), 2.60 (2H, q), 3.60 (3H, s), 3.73 (3H, s), 3.92 (2H, br.s), 4.93 (2H, s), 6.16 (2H, s)

20 (Reference example 11)

(2-Amino-4-methoxy-6-tetradecylphenoxy)methoxymethane
melting point: 46-48 °C

Reference example 12

25

(1) A mixture of 19.85 g of tert-butylhydroquinone, 10.7 ml of ethyl bromide and 200 ml of dimethylformamide (DMF) was cooled to -78 °C, and 4.82 g of 62.5 % sodium hydride was added to the mixture. The temperature of the mixture was raised to 0 °C, and the mixture was further stirred under ice-cooling for 30 minutes. The reaction mixture was poured into ice water, and the mixture was extracted with ethyl acetate. The extract was washed and dried, and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (solvent;

hexane : ethyl acetate = 10 : 1), and recrystallized from hexane to give 5.045 g of 4-ethoxy-2-tert-butylphenol (yield: 22 %, melting point: 96-98 °C).

- 5 (2) The product (3.328 g) thus obtained was treated in the same manner as described in Reference example 1 (1) to give 7.118 g of 2-(4-methoxyphenylazo)-4-ethoxy-6-tert-butylphenol (yield: 84 %, melting point: 105-108 °C).
- 10 (3) The product (7.06 g) thus obtained was treated in the same manner as described in Reference example 1 (2) and then the resulting material was purified by silica gel column chromatography (solvent; hexane : ethyl acetate = 10 : 1) to give 7.315 g of [2-(4-methoxyphenylazo)-4-ethoxy-6-
15 tert-butylphenoxy]methoxymethane (yield: 91 %, brown oily product, IR: 1600 cm⁻¹).

- (4) To a mixed solution of 7.31 g of the product thus obtained and 73 ml of methanol was added 1 g of 10 %
20 palladium-carbon (Pd-C). The mixture was subjected to catalytic reduction at normal temperature under normal pressure for one hour. After removing the catalyst by filtration, the filtrate was condensed under reduced pressure and the residue was purified by silica gel column
25 chromatography (solvent; hexane : ethyl acetate = 4 : 1) to give 4.51 g of (2-amino-4-ethoxy-6-tert-butylphenoxy)-methoxymethane (yield: 91 %, oily product, IR: 3464, 3373, 1615, 1593 cm⁻¹).

- 30 Reference examples 13 and 14

Corresponding starting materials were treated in the same manner as described in Reference example 12 to give the following compounds.

35

(Reference example 13)

(2-Amino-6-tert-butyl-4-hexyloxyphenoxy)methoxymethane
oily product

IR: 3466, 3374, 1594 cm^{-1}

5 (Reference example 14)

(2-Amino-6-tert-butyl-4-isopropyloxyphenoxy)methoxymethane
oily product

IR: 3464, 3373, 1591 cm^{-1}

10 Reference example 15

A mixture of 21.057 g of N,N-dimethyl-p-phenylenediamine,
18.2 ml of cycloheptanone and 100 ml of toluene was
refluxed for 4 hours by using a Dean-Stark's apparatus.

- 15 The solvent was removed under reduced pressure, and the
residue was dissolved in 200 ml of methanol. To the
solution was added 2 g of 10 % palladium-carbon (Pd-C), and
the mixture was subjected to catalytic reduction by using a
Parr's reduction apparatus at room temperature for 3 hours.
- 20 After removing the catalyst by filtration, the filtrate was
condensed and the residue was purified by silica gel column
chromatography (solvent; hexane : ethyl acetate = 3 : 2) to
give 29.478 g of N-4-dimethylaminophenyl-N-cycloheptylamine
(yield: 82 %, brown oily product, IR (film): 3375, 2926,
25 1517
 cm^{-1}).

Reference examples 16 to 48

- 30 Corresponding starting materials are treated in the same
manner as described in Reference example 15 to give the
compounds as shown in Table 25.

Table 25














































$\begin{array}{c} \text{R}^5 \\ \\ \text{HN}-\text{R}^6 \end{array}$			
Reference example	-R ⁵	-R ⁶	State
16			Oily product
17			Oily product
18			Oily product
19			Oily product
20			Oily product
21			Oily product
22			Oily product
23			Oily product
24			Oily product
25			Oily product
26			Oily product

Table 25 (contd.)

$\begin{array}{c} \text{R}^5 \\ \\ \text{HN}-\text{R}^6 \end{array}$			
Reference example	-R ⁵	-R ⁶	State
27			Oily product
28			Oily product
29			Oily product
30			Oily product
31			Oily product
32			Oily product
33			Oily product
34			Oily product
35			Oily product
36			Oily product

Table 25 (contd.)

$\begin{array}{c} R^5 \\ \\ HN-R^6 \end{array}$			
Reference example	-R ⁵	-R ⁶	State
37			Oily product
38			Oily product
39			Oily product
40			Oily product
41			Oily product
42			Oily product
43			Oily product
44			Oily product
45			Oily product
46			Oily product
47			Oily product
48			Oily product

Reference example 49

Under ice-cooling, to 30 ml of a THF solution containing 13.7 g of 1,4-diaminocyclohexane was added dropwise 30 ml
5 of a THF solution containing 8.73 g of di-tert-butyl dicarbonate. The mixture was stirred at the same temperature for 30 minutes and further at room temperature overnight. Then, THF was removed under reduced pressure and a saturated saline solution was added to the residue. The
10 mixture was extracted with ethyl acetate. The extract was washed and dried, and the solvent was removed to give 4.3 g of 1-tert-butoxycarbonylamino-4-aminocyclohexane (yield: 50 %, oily product, IR (KBr): 3343, 1683, 1525 cm^{-1}).

15 Reference example 50

p-Phenylenediamine was treated in the same manner as described in Reference example 49 to give N-tert-butoxycarbonyl-p-phenylenediamine (melting point: 115-116 °C).

20

Reference example 51

A mixture of 3.50 g of N,N-dimethyl-p-phenylenediamine, 4.592 g of heptanal, 9.095 g of triacetoxyborohydride,
25 1.841 g of acetic acid and 257 ml of dichloromethane was stirred at room temperature for one hour. A saturated sodium hydrogen carbonate solution is added to the mixture, and the mixture was extracted with ethyl acetate. The extract was washed and dried, and the solvent was removed
30 under reduced pressure. The residue obtained was purified by silica gel column chromatography (solvent; hexane : ethyl acetate = 2 : 1) to give 2.819 g of N,N-dimethyl-N'-heptyl-p-phenylenediamine (yield: 39 %, oily product, IR (film): 3375, 2927, 1519 cm^{-1}).

35

Reference example 52

N-benzyloxycarbonyl-4-aminocyclohexanone and aniline were treated in the same manner as described in Reference example 51 to give N-benzyloxycarbonyl-N'-phenyl-1,4-diaminocyclohexane.

Reference example 53

(1) Benzyloxycarbonyl chloride (12.4 ml) was added dropwise to a mixture of 10 g of trans-4-aminocyclohexanol, 13.3 ml of triethylamine and 300 ml of dichloromethane under ice-cooling, and the mixture was stirred at room temperature for one hour. The reaction mixture was washed and dried, and the solvent was removed under reduced pressure. The residue was recrystallized from an ethyl acetate solution to give 5.80 g of N-benzyloxycarbonyl-trans-4-aminocyclohexanol (yield: 27 %, melting point: 148-151 °C).

(2) To 1000 ml of dichloromethane suspension containing 25.9 g of pyridinium chlorochromate (PCC) was added dropwise under ice-cooling a mixture of 15 g of N-benzyloxycarbonyl-trans-4-aminocyclohexanol and 1000 ml of dichloromethane. The resulting mixture was stirred at room temperature for 4 hours. Then, diethyl ether was added to the reaction mixture and insoluble materials were removed by filtration from the mixture. The filtrate was condensed and the residue was purified by silica gel column chromatography (solvent; chloroform : methanol = 10 : 1) to give 10.562 g of N-benzyloxycarbonyl-4-aminocyclohexanone (yield: 71 %, melting point: 65-69 °C).

Reference example 54



Tetrabromomethane (19.4 g) was added to a mixture of 5.0 g of 2-cyclohexylethanol, 12.28 g of triphenylphosphine and

400 ml of dichloromethane, and the mixture was stirred at room temperature for 5 minutes. The mixture was washed and dried, and the solvent was removed under reduced pressure. The residue was applied to short silica gel column chromatography (solvent; hexane). A condensed eluate was dissolved in 50 ml of hexamethylphosphoramide (HMPA), and 5.31 g of N,N-dimethyl-p-phenylenediamine and 5.39 g of potassium carbonate were added to the solution. The resulting mixture was stirred at room temperature overnight. A saturated saline solution was added to the reaction mixture and the mixture was extracted with ethyl acetate. The extract was washed and dried, and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (solvent; chloroform : ethyl acetate = 2 : 1) to give 3.205 g of N'-(2-cyclohexylethyl)-N,N-dimethyl-p-phenylenediamine (yield: 33 %, brown oily product, IR (film): 3350, 1519 cm^{-1}).

Reference examples 55 and 56

Corresponding starting materials are treated in the same manner as described in Reference example 54 to give the compounds shown in Table 26.

Table 26

Reference example	$\begin{array}{c} \text{R}^5 \\ \\ \text{HN}-\text{R}^6 \end{array}$		
	$-\text{R}^5$	$-\text{R}^6$	Melting point ($^{\circ}\text{C}$), etc.
55		$-(\text{CH}_2)_2$ 	Oily product
56		$-(\text{CH}_2)_2$ 	82-85

Reference example 57

Under ice-cooling, 1.87 g of 62 % sodium hydride was added to 100 ml of a dimethylformamide (DMF) solution containing
5 10.00 g of N-benzyloxycarbonylaniline, and the mixture was stirred at room temperature for one hour. Under ice-cooling, to the above mixture was added dropwise 50 ml of a DMF solution containing 10.31 g of ethyl 6-bromohexanoate, and the resulting mixture was stirred at room temperature
10 overnight. DMF was removed under reduced pressure and water was added to the residue. The mixture was extracted with ethyl acetate. The extract was washed and dried, and the solvent was removed under reduced pressure. The residue was dissolved in 160 ml of methanol and 2 g of 10 %
15 palladium-carbon (Pd-C) was added to the solution. The mixture was subjected to catalytic reduction at normal temperature under normal pressure for 2 hours. After removing the catalyst by filtration, the filtrate was condensed and the residue was purified by silica gel column
20 chromatography (solvent; hexane : ethyl acetate = 4 : 1) to give 8.13 g of N-ethoxycarbonylpentyl-N-phenylamine (yield; 79 %, melting point: 34-37 °C).

Reference examples 58 to 76

25

Corresponding starting materials are treated in the same manner as described in Reference example 57 to give the compounds as shown in Table 27.

Table 27
















$\begin{array}{c} R^5 \\ \\ HN-R^6 \end{array}$			
Reference example	-R ⁵	-R ⁶	Melting point (°C), etc.
58		$-CH_2CH=C(CH_3)(CH_2)_2CH=C(CH_3)_2$	144-146
59		$-(CH_2)_4COOEt$	Powder
60		$-(CH_2)_5COOEt$	Oily product
61		$-(CH_2)_3COOEt$	Oily product
62		$-(CH_2)_6COOEt$	Oily product
63	$-CH_2-$ 	$-(CH_2)_5COOEt$	Oily product
64		$-(CH_2)_4COOEt$	Oily product
65		$-(CH_2)_6COOEt$	Oily product
66		$-(CH_2)_2COOEt$	Oily product
67	$-(CH_2)_{15}CH_3$	 -COOMe	94-95
68		$-CH_2COOEt$	Oily product
69		$-(CH_2)_5CH_3$	Oily product

Table 27 (contd.)

Reference example	$\begin{array}{c} R^5 \\ \\ HN-R^6 \end{array}$		
	$-R^5$	$-R^6$	Melting point (°C), etc.
70	$-(CH_2)_7CH_3$		Oily product
71	$-(CH_2)_{13}CH_3$		Oily product
72		$-(CH_2)_7CH_3$	Oily product
73		$-CH_2COOEt$	Oily product
74		$-CH_2-$ 	Dihydrochloride Oily product
75		$-(CH_2)_3COOEt$	Oily product
76		$-CH_2COOEt$	Oily product

Reference example 77

5
A mixture of 10.0 g of 4-octylaniline, 8.6 g of bromocycloheptane, 13.5 g of potassium carbonate and 50 ml of hexamethylphosphoramide (HMPA) was stirred at 90 to 100 °C for 7 hours. After cooling, a saturated saline solution
10 was added to the reaction mixture and the mixture was extracted with ethyl acetate. The extract was washed and dried, and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (solvent; hexane : ethyl acetate = 50 : 1) to give 7.79
15 g of N-cycloheptyl-N-(4-octylphenyl)amine (yield: 53 %, brown oily product, IR (film): 3390, 2925, 2854, 1617, 1518 cm^{-1}).

Reference examples 78 to 92

Corresponding starting materials are treated in the same manner as described in Reference example 77 to give the compounds as shown in Table 28.

Table 28























$\begin{array}{c} R^5 \\ \\ HN-R^6 \end{array}$			
Reference example	-R ⁵	-R ⁶	Melting point (°C), etc.
78		-(CH ₂) ₃ COOEt	Oily product
79		-(CH ₂) ₃ COOEt	Hydrobromide salt 196-199
80		-(CH ₂) ₃ COOEt	Oily product
81		-(CH ₂) ₃ COOEt	Hydrobromide salt 137-139
82		-(CH ₂) ₃ COOEt	Oily product
83		-(CH ₂) ₃ COOEt	Oily product
84		-CH ₂ - 	Oily product
85			Oily product

Table 28 (contd.)

Reference example	$\begin{array}{c} R^5 \\ \\ HN-R^6 \end{array}$		
	$-R^5$	$-R^6$	Melting point ($^{\circ}C$), etc.
86			85-88
87			Oily product
88			Oily product
89			Oily product
90			Oily product
91			Oily product
92		$-(CH_2)_3COOEt$	Oily product

Reference example 93

5

(1) A mixture of 6.92 g of N-benzyloxycarbonyl-2-iodoethylamine, 4.00 g of 1-benzylpiperazine, 15.66 g of potassium carbonate and 40 ml of hexamethylphosphoramide (HMPA) was stirred at room temperature for overnight.

10 Water was added to the reaction mixture, and the resulting mixture was extracted with diethyl ether. The extract was washed and dried, and the solvent was removed under reduced pressure. The residue was purified by silica gel column

chromatography (solvent; chloroform : methanol = 15 : 1) to
give 5.63 g of N-benzyloxycarbonyl-2-(4-benzylpiperazin-1-
yl)ethylamine (yield: 70 %, oily product, IR: 3230, 2910,
1710
5 cm⁻¹).







(2) To the product (2.29 g) thus obtained was added a 30 %
hydrogen bromide-acetic acid solution, and the mixture was
stirred at room temperature for one hour. Diethyl ether
10 was added to the reaction mixture and the resulting
crystals were collected by filtration. To the crystals
were added an aqueous saturated sodium hydrogen carbonate
solution, the mixture was extracted with chloroform, and
the chloroform layer was washed and dried. By removing the
15 solvent from the chloroform layer, 1.18 g of 2-(4-benzyl-
piperazin-1-yl)ethylamine (yield: 83 %, oily product, IR:
3350, 2930, 2850, 2800 cm⁻¹).

Reference examples 94 to 99

20

Corresponding starting materials are treated in the same
manner as described in Reference example 93 to give the
compounds as shown in Table 29.

Table 29

Reference example	H ₂ N-R ⁶	
	-R ⁶	Melting point (°C), etc.
94		Oily product
95		Oily product
96		Trihydrochloride >200
97		Oily product
98		Oily product
99		Oily product

Reference example 100

5

(1) A mixture of 3.7 g of N-(tert-butoxycarbonyl)piperazine, 2.5 g of bromodiphenylmethane, 6.9 g of potassium carbonate and 20 ml of hexamethylphosphoramide was stirred at 40 to 50 °C for 4 hours. After cooling, water was added and the reaction mixture was extracted with diethyl ether. The extract was washed and dried, and the solvent was removed under reduced pressure. Hexane was added to the precipitated crystals and the crystals were collected by

10

filtration to give 2.5 g of 4-(tert-butoxycarbonyl)-1-diphenylmethylpiperazine (melting point: 129-131 °C).

(2) The product (5.0 g) thus obtained was dissolved in 20 ml of 26 % hydrogen chloride-dioxane solution, and the mixture was stirred at room temperature for 30 minutes. The solvent was removed from the reaction mixture under reduced pressure. An aqueous 10 % potassium carbonate solution was added to the residue and the mixture was extracted with ethyl acetate. The extract was washed and dried, the solvent was removed under reduced pressure. Hexane was added to the precipitated crystals and the crystals were collected by filtration to give 3.1 g of 1-diphenylmethylpiperazine (melting point: 73-75 °C).

Reference example 101

(1) A mixture of 25 g of 2-(4-hydroxyphenyl)ethylamine hydrochloride, 36 g of sodium hydrogen carbonate, 200 ml of water and 200 ml of ethyl acetate was ice-cooled. 24.6 g of benzyloxycarbonyl chloride was added dropwise to the mixture. After stirring the mixture at room temperature for 20 hours, the organic layer was separated and washed, and the solvent was removed from the organic layer under reduced pressure. The residue was crystallized from a hexane solution to give 31 g of N-benzyloxycarbonylamino-2-(4-hydroxyphenyl)ethylamine (yield: 79 %, melting point: 94-97 °C).

(2) A mixture of 9.5 g of 3-chloropropanol, 37 ml of dibutylamine and 50 ml of dimethylsulfoxide was stirred at 70-80 °C for 8 hours. After cooling, water was added to the mixture and the mixture was extracted with ethyl acetate. The extract was washed and dried, and the solvent was removed from the mixture under reduced pressure. The residue was dissolved in 50 ml of chloroform, and under

ice-cooling, 8 ml of thionyl chloride was added dropwise to the solution. After stirring at 50 °C for 3 hours, the solvent was removed from the reaction mixture under reduced pressure. Water was added to the residue and the mixture
5 was washed with diethyl ether. The mixture was made alkaline with potassium carbonate and extracted with ethyl acetate. The extract was washed and dried, and the solvent was removed from the extract under reduced pressure. The residue was purified by silica gel column chromatography
10 (solvent; chloroform : ethanol = 20 : 1) to give 12 g of N,N-dibutyl-3-chloropropylamine (yield: 58 %, oily product).

NMR (δ ppm, CDCl_3): 0.91 (6H, s), 1.2-1.5 (8H, m), 1.88
15 (2H, q), 2.34-2.41 (4H, m), 2.53 (2H, t), 3.60 (2H, t)

(3) Under ice-cooling, to 20 ml of a dimethylformamide (DMF) suspension containing 850 mg of 62 % sodium hydride was added little by little 5.4 g of N-benzyloxycarbonyl-
20 amino-2-(4-hydroxyphenyl)ethylamine, and the mixture was stirred at room temperature for 20 minutes. Then, the mixture was ice-cooled, 10 ml of a DMF solution containing 4.5 g of N,N-dibutyl-3-chloropropylamine was added thereto. Further, after stirring the mixture at room temperature for
25 24 hours, water was added thereto and the mixture was extracted with diethyl ether. The extract was washed and dried, and the solvent was removed from the extract under reduced pressure. The residue was purified by silica gel column chromatography (solvent; hexane : ethyl acetate = 2
30 : 1 and then chloroform : ethanol = 20 : 1) to give 5.5 g of N-benzyloxycarbonyl-2-[4-(3-dibutylaminopropoxy)-phenyl]ethylamine (yield: 63 %, oily product, IR (film): 3310, 1710 cm^{-1}).

35 (4) Conc. hydrochloric acid (2.1 ml) and 1 g of 10 % palladium-carbon (Pd-C) were added to 100 ml of an ethanol

solution containing 5.4 g of N-benzyloxycarbonyl-2-[4-(3-dibutylaminopropoxy)phenyl]ethylamine. The mixture was subjected to catalytic reduction at normal temperature under normal pressure for 1.5 hours. After removing the catalyst by filtration, the filtrate was condensed and the residue was dissolved in water. The aqueous solution was washed with diethyl ether and made alkaline with potassium carbonate, and the mixture was extracted with ethyl acetate. The extract was washed and dried, and the solvent was removed under reduced pressure to give 3.2 g of 2-[4-(3-dibutylaminopropoxy)phenyl]ethylamine (yield: 85 %, oily product).


NMR (δ ppm, CDCl_3): 0.89 (6H, t), 1.2-1.5 (8H, m), 1.58 (2H, br.s), 1.90 (2H, q), 2.42 (4H, t), 2.59 (2H, t), 2.68 (2H, t), 2.92 (2H, t), 3.98 (2H, t), 6.81-7.11 (4H, m)

Reference example 102

Corresponding starting material is treated in the same manner as described in Reference example 101 to give the compound as shown in Table 30.

Table 30

25

Reference example	$\text{H}_2\text{N}-\text{R}^6$	Melting point ($^{\circ}\text{C}$), etc.
	$-\text{R}^6$	
102		Oily product

Reference example 103

Under ice-cooling, to 100 ml of a methanol solution containing 3.875 g of N-(4-piperidylmethyl)-N-benzylamine was added dropwise a mixed solution of 4.139 g of di-tert-butyl

dicarbonate ((Boc)₂O) and 20 ml of methanol. After stirring the mixture at the same temperature for 30 minutes, methanol was removed from the reaction mixture under reduced pressure and the residue was purified by silica gel
5 column chromatography (solvent; chloroform : methanol = 19 : 1) to give 2.72 g of N-(1-tert-butoxycarbonyl-piperidin-4-ylmethyl)-N-benzylamine (yield: 47 %, IR (film): 1693 cm⁻¹).

10 Reference example 104

Under ice-cooling, to 200 ml of a tetrahydrofuran (THF) solution containing 5.0 g of N-(4-piperidylmethyl)-N-benzylamine was added dropwise 50 ml of a THF solution
15 containing 2.9 ml of benzyl bromide. After stirring the mixture at the same temperature for one hour, THF was removed from the reaction mixture under reduced pressure and a saturated sodium hydrogen carbonate aqueous solution was added to the residue. The mixture was extracted with
20 ethyl acetate. The extract was washed and dried, and the solvent was removed under reduced pressure. Precipitated crystals were recrystallized from an ethanol solution to give 3.6 g of N-(1-benzylpiperidin-4-ylmethyl)-N-benzylamine (yield: 50 %, melting point: 240 °C or higher).

25

Reference example 105

Under ice-cooling, 3.46 g of benzyloxycarbonyl chloride was added dropwise to a mixed solution of 4.15 g of N-(4-
30 piperidylmethyl)-N-benzylamine, 2.10 g of triethylamine and 200 ml of THF. After stirring the mixture at the same temperature for 3 hours and then at room temperature for 2 hours, water was added to the mixture and the mixture was extracted with ethyl acetate. The extract was washed and
35 dried, and the solvent was removed under reduced pressure. The obtained residue was purified by silica gel column

chromatography (solvent; chloroform : methanol = 19 : 1) to give 3.41 g of N-(1-benzyloxycarbonylpiperidin-4-ylmethyl)-N-benzylamine (yield: 50 %, IR: 1702 cm^{-1}).

5 Reference example 106

4-Piperidylmethylamine and 3-formylpyridine were treated in the same manner as described in Reference example 2 to give N-(4-piperidylmethyl)-N-(3-pyridylmethyl)amine.

10

The product thus obtained and di-tert-butyl dicarbonate ((Boc)₂O) were treated in the same manner as described in Reference example 103 to give N-(1-tert-butoxycarbonylpiperidin-4-ylmethyl)-N-(3-pyridylmethyl)amine (IR: 3320, 15 1688 cm^{-1}).

Reference example 107

Under ice-cooling, 10 drops of a 50 % choline solution was added to a mixture of 20.0 g of 3-(trifluoromethyl)phenylhydrazine and 6.63 g of acrylonitrile, and the mixture was heated at 95 °C for one hour. After allowed to stand for cooling, 22 ml of 1N hydrochloric acid was added and the mixture was stirred at 95 °C for 10 minutes. After 25 subjecting the mixture to hot activated charcoal treatment, the mixture was adjusted to an alkaline pH with a 10 % aqueous sodium hydroxide solution under ice-cooling. Precipitated crystals were collected by filtration and washed, and recrystallized from a mixed solution of hexane and ethyl acetate to give 17.27 g of 1-[3-(trifluoro- 30 methyl)phenyl]-3-amino-2-pyrazoline (yield: 66 %, melting point: 104-107 °C).

Reference example 108

35

(1) A mixed solution of 20 g of 1,2,3-trimethoxybenzene

and 100 ml of tetrahydrofuran (THF) was cooled to -78 °C, and 140 ml of a hexane solution containing 1M sec-butyl lithium (sec-BuLi) was added dropwise thereto. After stirring the mixture at the same temperature for 45 minutes, 11 ml of dimethylformamide (DMF) was added to the reaction mixture. The mixture was stirred at -50 °C or lower for 45 minutes. Then, a 10 % acetic acid aqueous solution was added to the mixture, and the resulting mixture was extracted with diethyl ether. The extract was washed and dried, and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (solvent; hexane : ethyl acetate = 9 : 1) to give 5.7 g of 2,3,4-trimethoxybenzaldehyde (yield: 24 %, oily product).

(2) The product thus obtained was treated in the same manner as described in Reference example 3 to give (2-amino-4,5,6-trimethoxyphenoxy)methoxymethane (oily product).

NMR (δ ppm, CDCl_3): 3.57 (3H, s), 3.75 (3H, s), 3.77 (3H, s), 3.88 (3H, s), 3.6-3.8 (2H, br.s), 5.03 (2H, s), 6.08 (1H, s)

The phenol compound (1) or pharmaceutically acceptable salts thereof of the present invention have excellent inhibitory effects on lipid peroxidation, foam cell formation of macrophages, oxidized LDL formation, ACAT activity, mouse anti-oxidative action, reperfusion-induced arrhythmia, brain edema, carbon tetrachloride-induced hepatopathy and the like so that they are effective for the prevention and the treatment of ischemic diseases (cardiac infarction, cerebral infarction, reperfusion disorder, etc.), atherosclerosis, inflammation, hepatopathy and the like. Also, the desired compounds of the present invention have less toxicity and thus they are used as a medical compound in high safety.




* C L M S *

- 120 -


THIS SHEET HAS BEEN
REPLACED

Claims:

1. A phenol compound represented by the formula (1):



- 5 wherein R^0 represents hydrogen atom, an alkyl group which may be substituted or an alkyloxy group which may be substituted; R^1 represents an alkyl group which may be substituted; R^2 represents an alkyl group which may be substituted or an alkyloxy group which may be substituted; OR^3 represents a hydroxyl group which may be protected; R^4 represents hydrogen atom, a lower alkyl group or an acyl group each of which may be substituted; W represents O, S or NR^7 ; wherein R^7 represents hydrogen atom, an alkyl group, an aryl group, hydroxyl group or an alkyloxy group, a group of the formula (2):



- 15 represents an amino group which may be mono- or disubstituted or a heterocyclic group containing nitrogen atom,
20 or a pharmaceutically acceptable salt thereof.

- 25 2. The compound according to Claim 1, wherein R^5 and R^6 each may be the same or different and represent hydrogen atom, an alkyl group which may be substituted, an alkenyl group which may be substituted, an aryl group which may be substituted, an amino group which may be substituted or a heterocyclic group.

- 30 3. The compound according to Claim 2, wherein R^5 and R^6 may be the same or different, and each represents

This Sheet Has Been Replaced





* C L M S *

THIS SHEET HAS BEEN
REPLACED

- 121 -

- (1) an alkyl group which may be substituted by at least one substituent selected from the group consisting of an alkyl group, a halogenated alkyl group, a carboxyalkyl group, an alkyloxycarbonylalkyl group, a hydroxyalkyl group, a di-
5 hydroxyalkyl group, a trihydroxyalkyl group, an N-alkyl-aminoalkyl group, an N,N-dialkylaminoalkyl group, an N-(diphenylalkyl)aminoalkyl group, a carbamoylalkyl group, an N-alkylcarbamoylalkyl group, an N,N-dialkylcarbamoylalkyl group, an N-(dihydroxyalkyl)carbamoylalkyl group, a
10 morpholinocarbonylalkyl group, a heterocyclic group-substituted alkyl group, a cycloalkyl group, a cycloalkylalkyl group, an arylalkyl group and a diarylalkyl group;
- (2) an amino group which may be substituted by at least one substituent selected from the group consisting of an amino
15 group, a monoalkylamino group, a dialkylamino group, an arylamino group, an arylsulfonylamino group and an aryl-carbamoylamino group;
- (3) an alkenyl group which may be substituted by an alkyl group;
- 20 (4) an aryl group which may be substituted by at least one substituent selected from the group consisting of a phenyl group, an aminophenyl group, an N-alkylaminophenyl group and an N,N-dialkylaminophenyl group; or
- (5) a saturated or unsaturated 3 to 12-membered monocyclic
25 or dicyclic heterocyclic group having a hetero atom selected from sulfur atom, oxygen atom and nitrogen atom.

4. The compound according to Claim 3, wherein said heterocyclic group is a 5 to 10-membered monocyclic or dicyclic
30 heterocyclic group which may be mono-, di- or tri-substituted by 1 to 3 substituents selected from the group consisting of hydroxyl group, a hydroxyalkyl group, an alkyl-oxy group, an alkyloxycarbonyl group, an alkylcarbonyl group, an alkyl group, a cycloalkyl group, a cycloalkyl-
35 alkyl group, a pyridylalkyl group, oxo group, carboxyl group, phenyl group, a phenylalkyl group, a diphenylalkyl

This Sheet Has Been Replaced





* C L M S *

- 122 -

THIS SHEET HAS BEEN
REPLACED

group, phenylpiperazinyl group, a phenylalkyloxycarbonyl group, N-phenylcarbamoyl group and an N-phenylcarbamoyl-aminoalkyl group.

5 5. The compound according to Claim 4, wherein said hetero-
cyclic group is a heterocyclic group selected from the
group consisting of pyridyl group, pyridinio group, piper-
azinyl group, piperidyl group, pyrazolinyl group, imidazolyl
10 yl group, imidazolidinyl group, pyrrolidinyl group, morpholin-
yl group, pyradinyl group, benzimidazolyl group, quinolyl
group and tetrahydroquinolyl group.

6. The compound according to Claim 1, wherein R⁵ and R⁶
form a saturated or unsaturated 3 to 12-membered monocyclic
15 or dicyclic nitrogen-containing heterocyclic group together
with nitrogen atom adjacent thereto.

7. The compound according to Claim 6, wherein said nitro-
gen-containing heterocyclic group is a 5 to 10-membered
20 monocyclic or dicyclic heterocyclic group which may be
mono-, di- or tri-substituted by 1 to 3 substituents
selected from the group consisting of a halogen atom, an
alkyl group, hydroxyl group, a hydroxyalkyl group, an
alkyloxy group, oxo group, carboxyl group, an alkyloxy-
25 carbonyl group, a phenylalkylaminoalkyl group, phenyl
group, a halogenophenyl group, an aminophenyl group, a
nitrophenyl group, an aminophenylalkenyl group, an amino-
alkyl group, an aminophenylalkyl group, an N,N-diamino-
alkylaminophenylalkyl group, an N-arylhureidoalkyl group, a
30 morpholinylphenylalkyl group, a pyridylalkyl group, a benz-
imidazolylalkyl group, a hydroxyphenyl group, a diamino-
phenyl group, an N-alkylaminophenyl group, an N,N-dialkyl-
aminophenyl group, an amidinophenyl group, a piperadino-
phenyl group, a morpholinophenyl group, pyrrolidinyl group,
35 piperidyl group, indolyl group, pyrimidinyl group, benz-
imidazolyl group and pyridyl group.

This Sheet Has Been Replaced





THIS SHEET HAS BEEN
REPLACED

- 123 -


8. The compound according to Claim 7, wherein the hetero-
cyclic group is selected from piperazinyl group, piperidino
group, piperidyl group, morpholino group, morpholinyl
group, pyrrolidinyl group, thiomorpholinyl group, dihydro-
5 quinolyl group, tetrahydroquinolyl group and imidazolydiny
group.

9. The compound according to Claim 3, wherein R^0 is
hydrogen atom, R^1 is an alkyl group, R^2 is an alkyl group,
10 OR^3 is hydroxyl group, R^4 is hydrogen atom and W is oxygen
atom.

10. A compound selected from
2-[3-(3-pyridylmethyl)ureido]-4-methoxy-6-tert-butylphenol,
15 2-(3-cyclohexyl-3-phenylmethylureido)-4-methoxy-6-tert-
butylphenol,
2-[3-cycloheptyl-3-(4-dimethylaminophenyl)ureido]-4-meth-
oxy-6-tert-butylphenol,
2-[3,3-di(pyridylmethyl)ureido]-4-methoxy-6-tert-butyl-
20 phenol,
2-[4-(4-aminophenyl)piperazin-1-yl]amido-4-methoxy-6-tert-
butylphenol,
2-[3-(2-cyclohexylethyl)-3-(4-dimethylaminophenyl)ureido]-
4-methoxy-6-tert-butylphenol, and
25 2-[3-(4-pyridylmethyl)-3-(3-pyridyl)ureido]-4-methoxy-6-
tert-butylphenol.

11. A process for preparing a compound (1) according to
Claim 1 or a pharmaceutically acceptable salt thereof which
30 comprises the steps of

A) allowing a compound represented by the formula (c) or a
reactive derivative thereof:



This Sheet Has Been Replaced





THIS SHEET HAS BEEN
REPLACED

- 124 -


wherein R^0 , R^1 , R^2 and R^4 have the same meanings as defined in Claim 1, OR^{31} represents a hydroxyl group which may be protected; and W^1 represents oxygen atom or sulfur atom,

5 to react with a compound represented by the formula (b):




wherein NR^5R^6 represents an amino group which may be mono- or di-substituted, or a heterocyclic group containing nitrogen atom,

10 or a salt thereof to form a compound represented by the formula (1-a):



wherein the respective symbols have the same meanings as defined in Claim 1; or

15 B) allowing a compound represented by the formula (d):




wherein the respective symbols have the same meanings as defined in Claim 1,

or a salt thereof to react with a reactive derivative of a
20 compound represented by the formula (e):



wherein the respective symbols have the same meanings as defined in Claim 1,

to form a compound represented by the formula (1-b):



25

This Sheet Has Been Replaced




THIS SHEET HAS BEEN
REPLACED

- 125 -


wherein the respective symbols have the same meanings as defined in Claim 1; or

C) allowing the compound of the above formula (d) to react with a compound represented by the formula (f):




wherein R^{51} represents hydrogen atom, an alkyl group which may be substituted, an alkenyl group which may be substituted, an aryl group which may be substituted, an amino group which may be substituted or a heterocyclic group, and the other symbol has the same meaning as defined in Claim 1,

10 to form a compound represented by the formula (1-c):




wherein the respective symbols have the same meanings as defined in Claim 1; and,

15 D) when the W^1 of the product represented by the formula (1-a) or (1-c) is sulfur atom, if desired, allowing the product (1-a) or (1-c) to react with a compound represented by the formula (g):



wherein R^7 represents hydrogen atom, an alkyl group, an aryl group, hydroxyl group or an alkyloxy group, to form a compound of the formula (1-d):



25 wherein the respective symbols have the same meanings as defined above,

E) when the group OR^{31} of the product is a protected hydroxyl group, removing the protecting group of said hydroxyl group, if desired, or when the group OR^{31} of the

This Sheet Has Been Replaced





* C L M S *

THIS SHEET HAS BEEN
REPLACED

- 126 -

product is hydroxyl group, if desired, after protecting the hydroxyl group with a protecting group, and, if desired, converting the product to a pharmaceutically acceptable salt.

5

12. The process according to Claim 11, wherein when the group $-NR^5R^6$ in the product of the formula (1) is a group containing a protected carboxyl group, the process further comprises subjecting the product (1) to a deprotection
10 reaction to convert the product to a corresponding compound (1) wherein the group $-NR^5R^6$ is a group containing a free carboxyl group.

13. The process according to Claim 11, wherein when the
15 group $-NR^5R^6$ in the product of the formula (1) is a group containing a free carboxyl group, the process further comprises allowing the product (1) to react with a compound of the formula (h):



20 wherein $-NR^8R^9$ represents an amino group which may be mono- or di-substituted or a heterocyclic group containing a nitrogen atom, to convert the product to a compound (1) wherein the group $-NR^5R^6$ is a group containing a corresponding amido group.

25

14. The process according to Claim 11, wherein when the group $-NR^5R^6$ in the product of the formula (1) is a an unsubstituted or mono-substituted amino group, the process further comprises allowing the product (1) to react with an
30 alkylating agent of the formula (i):




wherein R^{10} represents an alkyl group which may be substituted and X represents an eliminatable group, to convert the product to a corresponding compound (1)
35 wherein the group $-NR^5R^6$ is a monoalkyl-substituted or dialkyl-substituted amino group.

This Sheet Has Been Replaced




ABSTRACT:

Disclosed are a phenol compound represented by the formula
(1):



wherein R^0 represents H, alkyl or alkyloxy; R^1 represents alkyl; R^2 represents alkyl or alkyloxy; OR^3 represents OH; R^4 represents H, lower alkyl or acyl, each of the above substituents may be substituted; W represents O, S or NR^7 ; where R^7 represents H, alkyl, aryl, OH or alkyloxy, a group of the formula (2):

10



represents an amino which may be mono- or di-substituted or heterocyclic group containing N atom,

15 or a pharmaceutically acceptable salt thereof, and a process for preparing the same.

This Sheet Has Been Replaced




-127- Substitute sheet - 21 March 1997


ABSTRACT

PHENOL COMPOUND AND PROCESS FOR PREPARING THE SAME

Disclosed are a phenol compound represented by the formula (1):



5 wherein R⁰ represents H, alkyl or alkyloxy; R¹ represents alkyl; R² represents alkyl or alkyloxy; OR³ represents OH; R⁴ represents H, lower alkyl or acyl, each of the above substituents may be substituted; W represents O, S or NR⁷; where R⁷ represents H, alkyl, 10 aryl, OH or alkyloxy, a group of the formula (2):




represents an amino which may be mono- or di-substituted or heterocyclic group containing N atom, 15 or a pharmaceutically acceptable salt thereof, and a process for preparing the same.




Claims:

1. A phenol compound represented by the formula (1):



wherein R^0 represents hydrogen atom, an alkyl group which may be substituted or an alkyloxy group which may be substituted; R^1 represents an alkyl group which may be substituted; R^2 represents an alkyl group which may be substituted or an alkyloxy group which may be substituted; OR^3 represents a hydroxyl group which may be protected by an acyl group, a lower alkyloxy-lower alkyl group, a lower alkyloxycarbonyl group, a lower alkylcarbonyloxy-lower alkyl group or an aralkyl group;

R^4 represents hydrogen atom, a lower alkyl group or an acyl group each of which may be substituted; W represents O, S or NR^7 ; wherein R^7 represents hydrogen atom, an alkyl group, an aryl group, hydroxyl group or an alkyloxy group, a group of the formula (2):



represents ⁽ⁱ⁾ an amino group which may be mono- or di-substituted by

(a) an alkyl

group, a halogenated alkyl group, a carboxyalkyl group, an alkyloxycarbonylalkyl group, a hydroxyalkyl group, a dihydroxyalkyl group, a trihydroxyalkyl group, an N-alkyl-aminoalkyl group, an N,N-dialkylaminoalkyl group, an N-(diphenylalkyl)aminoalkyl group, a carbamoylalkyl group, an N-alkylcarbamoylalkyl group, an N,N-dialkylcarbamoylalkyl group, an N-(dihydroxyalkyl)carbamoylalkyl group, a morpholinocarbonylalkyl group, a heterocyclic group-substituted alkyl group, a cycloalkyl group, a cycloalkylalkyl group, an arylalkyl group or a diarylalkyl group;

Date: **26 DEC 1997**

(b) an amino group,

a monoalkylamino group, a dialkylamino group, an arylamino group, an arylsulfonylamino group or an aryl-carbamoylamino group;

(c) an alkenyl group which may be substituted by an alkyl group;

(d) an aryl group which may be substituted by at least one substituent selected from the group consisting of

an amino group, an N-alkylamino group and an N,N-dialkylamino group; or

(e) a saturated or unsaturated 3 to 12-membered monocyclic or dicyclic heterocyclic group having a hetero atom selected from sulfur atom, oxygen atom and nitrogen atom

or (ii) a heterocyclic group containing nitrogen atom, or a pharmaceutically acceptable salt thereof.

said aryl group is phenyl group or naphthyl group.

~~2. The compound according to Claim 1, wherein R^1 and R^2 each may be the same or different and represent hydrogen atom, an alkyl group which may be substituted, an alkenyl group which may be substituted, an aryl group which may be substituted, an amino group which may be substituted or a heterocyclic group.~~

~~3. The compound according to Claim 2, wherein R^5 and R^6 may be the same or different, and each represents~~

- ~~(1) an alkyl group which may be substituted by at least one~~
substituent selected from the group consisting of an alkyl
group, a halogenated alkyl group, a carboxyalkyl group, an
alkyloxycarbonylalkyl group, a hydroxyalkyl group, a di-
hydroxyalkyl group, a trihydroxyalkyl group, an N-alkyl-
aminoalkyl group, an N,N-dialkylaminoalkyl group, an N-
(diphenylalkyl)aminoalkyl group, a carbamoylalkyl group, an
N-alkylcarbamoylalkyl group, an N,N-dialkylcarbamoylalkyl
group, an N-(dihydroxyalkyl)carbamoylalkyl group, a
morpholinocarbonylalkyl group, a heterocyclic group-sub-
stituted alkyl group, a cycloalkyl group, a cycloalkylalkyl
group, an arylalkyl group and a diarylalkyl group;
- (2) an amino group which may be substituted by at least one
substituent selected from the group consisting of an amino
group, a monoalkylamino group, a dialkylamino group, an
arylamino group, an arylsulfonylamino group and an aryl-
carbamoylamino group;
- (3) an alkenyl group which may be substituted by an alkyl
group;
- (4) an aryl group which may be substituted by at least one
substituent selected from the group consisting of a phenyl
group, an aminophenyl group, an N-alkylaminophenyl group
and an N,N-dialkylaminophenyl group; or
- (5) a saturated or unsaturated 3 to 12-membered monocyclic
or dicyclic heterocyclic group having a hetero atom
~~selected from sulfur atom, oxygen atom and nitrogen atom.~~

~~3~~
~~4~~ The compound according to Claim ~~3~~¹, wherein said hetero-
cyclic group is a 5 to 10-membered monocyclic or dicyclic
heterocyclic group which may be mono-, di- or tri-substi-
tuted by 1 to 3 substituents selected from the group con-
sisting of hydroxyl group, a hydroxyalkyl group, an alkyl-
oxy group, an alkyloxycarbonyl group, an alkylcarbonyl
group, an alkyl group, a cycloalkyl group, a cycloalkyl-
alkyl group, a pyridylalkyl group, oxo group, carboxyl
group, phenyl group, a phenylalkyl group, a diphenylalkyl



26 DEC 1997

Date

group, phenylpiperazinyl group, a phenylalkyloxy-carbonyl group, N-phenylcarbamoyl group and an N-phenylcarbamoyl-aminoalkyl group.

~~5~~⁴. The compound according to Claim ~~4~~³, wherein said heterocyclic group is a heterocyclic group selected from the group consisting of pyridyl group, pyridinio group, piperazinyl group, piperidyl group, pyrazolinyl group, imidazolyl group, imidazolidinyl group, pyrrolidinyl group, morpholinyl group, pyradinyl group, benzimidazolyl group, quinolyl group and tetrahydroquinolyl group.

~~6~~⁵. The compound according to Claim 1, wherein R⁵ and R⁶ form a saturated or unsaturated 3 to 12-membered monocyclic or dicyclic nitrogen-containing heterocyclic group together with nitrogen atom adjacent thereto.

~~7~~⁶. The compound according to Claim ~~6~~⁵, wherein said nitrogen-containing heterocyclic group is a 5 to 10-membered monocyclic or dicyclic heterocyclic group which may be mono-, di- or tri-substituted by 1 to 3 substituents selected from the group consisting of a halogen atom, an alkyl group, hydroxyl group, a hydroxyalkyl group, an alkyloxy group, oxo group, carboxyl group, an alkyloxy-carbonyl group, a phenylalkylaminoalkyl group, phenyl group, a halogenophenyl group, an aminophenyl group, a nitrophenyl group, an aminophenylalkenyl group, an aminoalkyl group, an aminophenylalkyl group, an N,N-diaminoalkylaminophenylalkyl group, an N-aryldureidoalkyl group, a morpholinylphenylalkyl group, a pyridylalkyl group, a benzimidazolylalkyl group, a hydroxyphenyl group, a diaminophenyl group, an N-alkylaminophenyl group, an N,N-dialkylaminophenyl group, an amidinophenyl group, a piperadinophenyl group, a morpholinophenyl group, pyrrolidinyl group, piperidyl group, indolyl group, pyrimidinyl group, benzimidazolyl group and pyridyl group.




* C L M S *

7
~~8~~. The compound according to Claim 6
~~7~~, wherein the hetero-
cyclic group is selected from piperazinyl group, piperidino
group, piperidyl group, morpholino group, morpholinyl
group, pyrrolidinyl group, thiomorpholinyl group, dihydro-
quinolyl group, tetrahydroquinolyl group and imidazolydinyl
group.

8
~~9~~. The compound according to Claim 1
~~2~~, wherein R⁰ is
hydrogen atom, R¹ is an alkyl group, R² is an alkyl group,
OR³ is hydroxyl group, R⁴ is hydrogen atom and W is oxygen
atom.

9
~~10~~. A compound selected from
2-[3-(3-pyridylmethyl)ureido]-4-methoxy-6-tert-butylphenol,
2-(3-cyclohexyl-3-phenylmethylureido)-4-methoxy-6-tert-
butylphenol,
2-[3-cycloheptyl-3-(4-dimethylaminophenyl)ureido]-4-meth-
oxy-6-tert-butylphenol,
2-[3,3-di(pyridylmethyl)ureido]-4-methoxy-6-tert-butyl-
phenol,
2-[4-(4-aminophenyl)piperazin-1-yl]amido-4-methoxy-6-tert-
butylphenol,
2-[3-(2-cyclohexylethyl)-3-(4-dimethylaminophenyl)ureido]-
4-methoxy-6-tert-butylphenol, and
2-[3-(4-pyridylmethyl)-3-(3-pyridyl)ureido]-4-methoxy-6-
tert-butylphenol.


10
~~11~~. A process for preparing a compound (1) according to
Claim 1 or a pharmaceutically acceptable salt thereof which
comprises the steps of
A) allowing a compound represented by the formula (c) or a
reactive derivative thereof:




wherein R^0 , R^1 , R^2 and R^4 have the same meanings as defined in Claim 1, OR^{31} represents a hydroxyl group which may be protected by an acyl group, a lower alkyloxy-lower alkyl group, a lower alkyloxycarbonyl group, a lower alkylcarbonyloxy-lower alkyl group or an aralkyl group;

and W^1 represents oxygen atom or sulfur atom,

to react with a compound represented by the formula (b):




or a salt thereof to form a compound represented by the formula (1-a):



wherein the respective symbols have the same meanings as defined in Claim 1; or

B) allowing a compound represented by the formula (d):




wherein the respective symbols have the same meanings as defined in Claim 1,

or a salt thereof to react with a reactive derivative of a compound represented by the formula (e):



wherein the respective symbols have the same meanings as defined in Claim 1,

to form a compound represented by the formula (1-b):



wherein the respective symbols have the same meanings as defined in Claim 1; or

C) allowing the compound of the above formula (d) to react with a compound represented by the formula (f):



wherein R^{51} represents hydrogen atom,

(a) an alkyl

group, a halogenated alkyl group, a carboxyalkyl group, an
alkyloxycarbonylalkyl group, a hydroxyalkyl group, a di-
hydroxyalkyl group, a trihydroxyalkyl group, an N-alkyl-
aminoalkyl group, an N,N-dialkylaminoalkyl group, an N-
(diphenylalkyl)aminoalkyl group, a carbamoylalkyl group, an
N-alkylcarbamoylalkyl group, an N,N-dialkylcarbamoylalkyl
group, an N-(dihydroxyalkyl)carbamoylalkyl group, a
morpholinocarbonylalkyl group, a heterocyclic group-sub-
stituted alkyl group, a cycloalkyl group, a cycloalkylalkyl
group, an arylalkyl group or a diarylalkyl group;

(b) an amino group,

a monoalkylamino group, a dialkylamino group, an
aryl amino group, an arylsulfonylamino group or an aryl-
carbamoylamino group;

(c) an alkenyl group which may be substituted by an alkyl
group;

(d) an aryl group which may be substituted by at least one
substituent selected from the group consisting of


an amino group, an N-alkylamino group
and an N,N-dialkylamino group; or

(e) a saturated or unsaturated 3 to 12-membered monocyclic
or dicyclic heterocyclic group having a hetero atom
selected from sulfur atom, oxygen atom and nitrogen atom,

and the other symbol has the same meaning as defined in Claim 1,



to form a compound represented by the formula (1-c):




wherein the respective symbols have the same meanings as defined in Claim 1; and,

D) when the W^1 of the product represented by the formula (1-a) or (1-c) is sulfur atom, if desired, allowing the product (1-a) or (1-c) to react with a compound represented by the formula (g):



wherein R^7 represents hydrogen atom, an alkyl group, an aryl group, hydroxyl group or an alkyloxy group, to form a compound of the formula (1-d):



wherein the respective symbols have the same meanings as defined above,

E) when the group OR^{31} of the product is a protected hydroxyl group, removing the protecting group of said hydroxyl group, if desired, or when the group OR^{31} of the



product is hydroxyl group, if desired, after protecting the hydroxyl group with a protecting group, and, if desired, converting the product to a pharmaceutically acceptable salt.

11
~~12~~ The process according to Claim 10
~~11~~, wherein when the group $-NR^5R^6$ in the product of the formula (1) is a group containing a protected carboxyl group, the process further comprises subjecting the product (1) to a deprotection reaction to convert the product to a corresponding compound (1) wherein the group $-NR^5R^6$ is a group containing a free carboxyl group.

12
~~13~~ The process according to Claim 10
~~12~~, wherein when the group $-NR^5R^6$ in the product of the formula (1) is a group containing a free carboxyl group, the process further comprises allowing the product (1) to react with a compound of the formula (h):



wherein $-NR^8R^9$ represents an amino group which may be mono- or di-substituted or a heterocyclic group containing a nitrogen atom,

to convert the product to a compound (1) wherein the group $-NR^5R^6$ is a group containing a corresponding amido group.

13
~~14~~ The process according to Claim 11, wherein when the group $-NR^5R^6$ in the product of the formula (1) is a an unsubstituted or mono-substituted amino group, the process further comprises allowing the product (1) to react with an alkylating agent of the formula (i):



wherein R^{10} represents an alkyl group which may be substituted and X represents an eliminatable group, to convert the product to a corresponding compound (1) wherein the group $-NR^5R^6$ is a monoalkyl-substituted or dialkyl-substituted amino group.



* C L M S *

This Sheet Has Been Replaced



REPLACEMENT SHEET

Date: **16 APR 1998**

Substitute Sheet - 14 April 1998

- 126 -

product is hydroxyl group, if desired, after protecting the hydroxyl group with a protecting group, and, if desired, converting the product to a pharmaceutically acceptable salt.

11
~~12.~~ The process according to Claim 10~~11~~, wherein when the group $-NR^5R^6$ in the product of the formula (1) is a group containing a protected carboxyl group, the process further comprises subjecting the product (1) to a deprotection reaction to convert the product to a corresponding compound (1) wherein the group $-NR^5R^6$ is a group containing a free carboxyl group.

12
~~13.~~ The process according to Claim 10~~11~~, wherein when the group $-NR^5R^6$ in the product of the formula (1) is a group containing a free carboxyl group, the process further comprises allowing the product (1) to react with a compound of the formula (h):



wherein $-NR^8R^9$ represents an amino group which may be mono- or di-substituted or a heterocyclic group containing a nitrogen atom, to convert the product to a compound (1) wherein the group $-NR^5R^6$ is a group containing a corresponding amido group.

13
~~14.~~ The process according to Claim 10~~11~~, wherein when the group $-NR^5R^6$ in the product of the formula (1) is a an unsubstituted or mono-substituted amino group, the process further comprises allowing the product (1) to react with an alkylating agent of the formula (i):



wherein R^{10} represents an alkyl group which may be substituted and X represents an eliminatable group, to convert the product to a corresponding compound (1) wherein the group $-NR^5R^6$ is a monoalkyl-substituted or dialkyl-substituted amino group.

New Sheet - 14 April 1998

- 126a -

14. A pharmaceutical preparation which comprises a therapeutically effective amount of a phenol compound or a pharmaceutically acceptable salt thereof as set forth in either one of claims 1 to 9 in an admixture with a conventional pharmaceutically acceptable carrier or diluent.

15. The use of a compound as defined in any claims 1 to 9 or a pharmaceutically acceptable salt thereof for the treatment or prevention of atherosclerosis, cardiac infarction, cell damage or arrhythmia at ischemia/reperfusion, inflammation or hepatopathy.